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Abstract
Membrane-type 1 matrix metalloproteinase (MT1-MMP) is an integral multidomain
membrane protease involved in extracellular matrix remodelling. No longer recognized
solely as a destructive enzyme, MT1-MMP proteolytic and non-proteolytic activities are
involved in a variety of cellular processes. I hypothesized that the diverse functions of MT1MMP are dependent on domain-specific binding partner interactions that elicit a cellular
response. Using a combination of co-immunoprecipitation and mass spectrometry, 248
unique proteins were isolated in MT1-MMP variant expressing MCF-7 cells. Newly
identified binding partners suggest potential roles of MT1-MMP in the nucleus, endoplasmic
reticulum, cytoplasm, and plasma membrane. Additionally, the cytoplasmic domain of MT1MMP attenuates canonical transforming growth factor beta (TGF-β) signalling through an
unknown mechanism. The results of this proteomic study add proteins to a growing catalogue
of binding partners involved in proper localization and function of MT1-MMP.

Keywords
ECM remodelling
matrix metalloproteinase (MMP)
membrane-type 1 matrix metalloproteinase (MT1-MMP)
MCF-7
co-immunoprecipitation
mass spectrometry
transforming growth factor beta (TGF-β)

ii

Summary for Lay Audience
The extracellular matrix (ECM) is an interconnected network of proteins that provides
structural support to cells, tissues, and organ systems. For cells, the building blocks of life, to
migrate to new places within a growing organism, the ECM needs to be remodelled. It is
important to note that migration is necessary for proper development and function, but
abnormal cell migration is involved in various pathologies. Matrix metalloproteinases
(MMPs) are proteins secreted by the cell into the ECM, where they function to break down
the ECM so the cell can move freely. There are many types of MMPs that can collectively
degrade all the different parts of the ECM. In my project, I studied membrane-type 1 matrix
metalloproteinase (MT1-MMP). Early research deemed MT1-MMP a destructive enzyme
observed in cancerous tissue. However, MT1-MMP not only degrades the ECM so the cell
can move, but part of this protein extends into the cell (cytoplasmic domain), where it is
observed to communicate to the cell when and where to migrate. For this reason, MT1-MMP
is described as a multifunctional protease. The purpose of my research was to further
investigate the function of MT1-MMP, more specifically through its interaction with other
proteins. Here, 248 proteins were identified that associate with MT1-MMP in breast cancer
cells. These newly identified proteins point to possible novel interactions and functions of
MT1-MMP throughout the cell, not just its role as an enzyme. Additionally, removal of the
cytoplasmic domain induces transforming growth factor beta (TGF-β) signalling, an
important regulator of cellular processes. TGF-β signalling, in addition to having critical
embryonic roles, has dual functions in tumours, acting either as a suppressor or activator.
Understanding what MT1-MMP interacts with is critical due to its involvement in many
important processes in development, wound healing, and disease.
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1

INTRODUCTION

1.1

Extracellular matrix

The extracellular matrix (ECM) is a heterogenous, three-dimensional network of secreted
macromolecules that provides structural support to the embedded cells. Composed
primarily of water, polysaccharides, and proteins, the composition and structure of the
ECM influences the function of cells in tissues (Theocharis et al., 2016). Matrix
components bind to each other as well as cell adhesion receptors, typically integrins, with
which cells integrate signals from the ECM. It is important to note that cell-ECM
interactions are reciprocal. All cell types locally synthesize and secrete ECM
macromolecules, which in turn can influence the behaviour of surrounding cells (Kim et
al., 2011). For this reason, the ECM is important for cellular growth, migration,
differentiation, survival, homeostasis, and morphogenesis (Clause and Barker, 2013;
Frantz et al., 2010).
Structurally, the ECM can be classified into two components: the interstitial matrix and
basement membrane. These two domains share a basic structure defined by a collagen
scaffold, but the types of collagen and resulting three-dimensional structure are
drastically different (Bosman and Stamenkovic, 2003). The interstitial matrix is primarily
deposited by stromal cells and composed of fibrillar collagens, proteoglycans, and
glycoproteins that contribute to the tensile strength of the tissue (Egeblad et al., 2010; Lu
et al., 2012). The basement membrane is a sheet-like barrier produced jointly by
epithelial, endothelial, and stromal cells. Composed primarily of type IV collagen,
laminins, fibronectin, and linker proteins, the basement membrane is much more compact
and less porous than the interstitial matrix (Egeblad et al., 2010; Lu et al., 2012).
Separating epithelial cells from the surrounding stroma, the basement membrane is a
specialized form of ECM that is not only crucial to maintain cell polarity, but also serves
to support and inhibit the movement of cells (Kalluri, 2003; Pöschl et al., 2004). The
mechanisms involved in the process of cell movement are well understood. In brief, a
migrating cell will become polar in which actin-based membrane protrusions will adhere
to specific ECM substrate through cell surface integrins, giving polarity to the cell
(leading edge). As the cell advances, posterior focal adhesions will detach to facilitate
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forward movement of the cell body (trailing edge) (Trepat et al., 2012). Coordinated
movement of the cell is primarily guided by cell-ECM and cell-cell cues (Reig et al.,
2014). With this in mind, the ECM is not only a physical scaffold supporting the cell, but
also a reservoir of biologically active molecules that can modulate cell movement (Chirco
et al., 2006; Egeblad and Werb, 2002).
Independent of its structural function, the biochemical properties of the ECM rely on its
association with growth factors, cytokines, and chemokines within the matrix that allow
cells to sense and interact with their environment through various signal transduction
cascades. Signalling molecules that elicit a cellular response can be sequestered within
the ECM, limiting diffusion and maintaining homeostasis. Then, at a developmentally or
physiologically relevant time, these molecules can be locally released from the matrix
through proteolytic processing (Theocharis et al., 2016). For example, vascular
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 2 bind to heparan
sulfate proteoglycans, and are sequestered in the ECM (Ortéga et al., 1998; Robinson and
Stringer, 2001; Walker et al., 1994). This retention creates a chemical gradient important
during development for proper cell differentiation (Hynes, 2009). The interaction
between FGF-2 and heparan sulfate is also required for binding to, and stabilization of,
the FGF receptors (Rapraeger et al., 1991; Schlessinger et al., 2000; Yayon et al., 1991).
Through sequestering and release of signalling molecules, the ECM can indirectly
influence cell behaviour. However, ECM proteins themselves can serve as ligands for cell
receptors, thus directly affecting cell function. Laminin, an integral ECM glycoprotein,
contains multiple epidermal growth factor (EGF)-like domains which may bind to EGF
receptors (EGFR) (Engel, 1989). When presented as soluble ligands, laminin EGF-like
domains were able to modulate signalling through EGFR (Panayotou et al., 1989; Schenk
et al., 2003). Many such domains are found within ECM proteins in various arrangements
and combinations so it is hypothesized that these domains can be released by proteolysis
to act as soluble ligands (Hynes, 2009).
Cells are constantly remodelling the ECM through synthesis, degradation, and subsequent
reassembly of matrix proteins – especially during cell migration and invasion. As
described, the basement membrane directly underlies epithelial and endothelial cells
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where it functions as a barrier of cell invasion. With a thickness of approximately 100300 nm, the collagen IV scaffold of the basement membrane is densely compact with a
pore size of approximately 50 nm between fibers (Abrams et al., 2000). As the typical
permissive size for cell movement is 2 μm, the ECM must be remodelled for migration to
occur, a process that includes protease-mediated degradation (Rowe and Weiss, 2009).
During embryogenesis, remodelling occurs during large-scale migration events such as
gastrulation, neurulation, and other processes in which cells undergo epithelialmesenchymal transition (EMT). All of these involve disruption of cell-cell and cell-ECM
adhesion as well as turnover of the ECM (Ohta et al., 2010). The mechanisms mediating
ECM remodelling are also associated with many diseases including breast cancer, in
which excessive ECM degradation seemingly allows the invasion of epithelial cells
(Bonnans et al., 2014). Important for cell migration and invasion during development, but
also unregulated in various pathologies, the ECM is a dynamic structure that is
remodelled and degraded by proteases.
The importance of ECM remodelling during development has been studied for decades.
The first vertebrate collagenolytic factor was identified by Gross and Lapiere (1962) in
tadpole tissues (skin, gut, and gills) undergoing metamorphosis, establishing the field of
protease-mediated ECM remodelling research. To date, the MEROPS database has
identified over 600 individual peptidases and 1600 inhibitors in the human degradome.
Based on the nucleophile involved in catalysis, the degradome can be divided into
aspartic proteases, cysteine proteases, metalloproteases, mixed proteases, serine
proteases, and threonine proteases (Figure 1) (Rawlings et al., 2014). Cysteine, serine,
and threonine proteases utilize their respective amino acid side chains as a nucleophile,
while mixed proteases are capable of using a combination of the three (Rawlings et al.,
2014). In contrast, aspartic proteases and metalloproteases use an activated water
molecule to mediate the nucleophilic attack of a peptide bond (James, 2004; Murphy and
Nagase, 2008). Although proteases in each clan contain the same nucleophile in the
catalytic site, the molecular structures, catalytic mechanism, and sequence homology can
be very different between individual proteases (Rawlings et al., 2014). Proteases are
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Figure 1. Classification of proteases in the human degradome
To date, MEROPS database has identified over 600 known and putative peptidases
within the human degradome. They can be classified into six groups – aspartic, cysteine,
mixed, serine, threonine, and metalloproteases – as based on the nucleophile involved in
catalysis. Aspartic proteases and metalloproteases activate a water molecule to cleave a
peptide bond. In contrast, serine, cysteine, and threonine proteases utilize their
corresponding amino acid side chains, with mixed proteases capable of using a
combination of the three (Rawlings et al., 2014).
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further divided into families that share significant sequence homology to a prototypical
representative of the family, usually the peptidase that has been most studied (Rawlings
et al., 2014). Matrix metalloproteinases are a family of proteases that have been wellstudied because they are the primary enzymes involved in ECM remodelling.
1.2

Matrix metalloproteinases

Matrix metalloproteinases (MMPs), or matrixins, are a subfamily of zinc-dependent
endopeptidases with amino acid sequence similarity to the catalytic domain of human
fibroblast collagenase 1 (MMP-1) (Rawlings et al., 2014). In total, there are 24 matrixin
genes in the human genome, but only 23 unique MMP proteins due to a duplication of
MMP23. As members of the metzincin superfamily of proteases, the catalytic domain
contains a zinc-binding motif (HEXXHXXGXXH) and a conserved methionine (“Metturn”) eight residues downstream (Bode et al., 1993; Murphy et al., 1991). This sequence
creates an active site in which the three histidines ligated to a catalytic Zn2+ ion rest on
the conserved “Met-turn” - a hydrophobic base - for further support of the structure. The
glutamate within the zinc-binding motif aids in polarizing a Zn2+-bound water molecule.
During a series of transition states, the Zn2+-bound water executes a nucleophilic attack
of the target peptide’s carbonyl carbon, resulting in the breakdown of the peptide bond
between the carboxyl group and amino group of two linked amino acids, as well as the
release of a water molecule (Bode et al., 1999; Jacobsen et al., 2010; Park et al., 2003;
Pelmenschikov and Siegbahn, 2002). MMPs are distinguished from other metzincins by
their synthesis as pre-proenzymes with a “cysteine switch” motif (PRCGXPD), which
maintains the newly translated enzyme in a latent state (Figure 2a) (Van Wart and
Birkedal-Hansen, 1990). The signal peptide of a pre-proMMP is removed during
translation, but the proMMP remains inactive due to the cysteine sulfhydryl group within
the pro-domain chelating the active site Zn2+ (Van Wart and Birkedal-Hansen, 1990).
Disruption of the zinc-thiol interaction is required for the zymogen to acquire activity,
typically by protease-mediated removal of the pro-domain (Ra and Parks, 2007; Van
Wart and Birkedal-Hansen, 1990). However, proMMPs can also be activated by various
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Figure 2. Classification of matrix metalloproteinases within the human degradome
(a) Due to the diversity of the human degradome, enzymes are categorized following the
ranking scheme of clan, subclan, family, and subfamily. Clan MA: Clan MA contains a
variety of metallopeptidases identified by an HEXXH motif. Two histidines stabilize a
catalytic Zn2+ ion while a nearby glutamic acid polarizes the Zn2+-bound water molecule
to cleave the peptide. Subclan MA(M): Clan MA is further divided into subclan MA(M)
in which these peptidases are synthesized as inactive zymogens. Family M10:
Metzincins, classified as family M10, contain the motif HEXXHXXGXXH and a
methionine located 7 amino acids C-terminal to the last His. Expanding upon the clan
MA motif, the third His is involved in stabilizing the catalytic Zn2+. The conserved
methionine forms a hydrophobic base - a structure identified as a “Met-turn” - which
supports the catalytic site (Bode et al., 1993). The metzincin family includes various
subfamilies differing in the mechanism of activation. Subfamily M10A: Matrix
metalloproteases (MMPs), termed matrixins as part of subfamily M10A, are a mosaic
group of 23 unique proteins that remain inactive due to a “cysteine switch” (Van Wart
and Birkedal-Hansen, 1990). Synthesized as pre-proenzymes, an inhibitory pro-domain
contains a PRCGXPD motif in which the cysteine sulfhydryl group chelates the active
site Zn2+, preventing interaction with a water molecule. (b) Structure: Save for MMP-7,
MMP-23, and MMP-26, matrix metalloproteases typically share a common core structure
of a propeptide, catalytic domain, linker region, and hemopexin domain.
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ectopic mechanisms that perturb the conformation or free the thiol (Springman et al.,
1990; Van Wart and Birkedal-Hansen, 1990).
Matrix metalloproteinases are classified by two independent characteristics: substrate
preference and cellular localization. They can be divided into collagenases (MMP-1, -8,
and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, and -11), matrilysins
(MMP-7 and -26), membrane-bound (MMP-14, -15, -16, -17, -24, and -25), and other
MMPs (MMP-12, -19, -20, -21, -23, -27, and -28) as based on domain organization and
ECM substrate affinity. Each MMP has distinct yet overlapping substrate specificities,
but together they can process virtually all ECM proteins (Sternlicht and Werb, 2001).
Because of this, a more common classification of MMPs is based on their cellular
localization. A majority of MMPs are soluble and commonly secreted into the ECM as
zymogens (proMMPs). In contrast, membrane-type MMPs are anchored to the cell
membrane after their pro-domains are removed in the Golgi, and thus are proteolytically
active. Membrane-type 1, 2, 3, and 5 MMPs contain a type 1 transmembrane domain
followed by a cytoplasmic domain, whereas MT4-MMP and MT6-MMP are
glycosylphosphatidylinositol-anchored to the plasma membrane (Itoh et al., 1999;
Kojima et al., 2000; Sato et al., 1994). Typically, MMPs share a common structure: a
propeptide of about 80 amino acids, a catalytic domain of about 170 amino acids, a linker
or hinge region of variable length, and a hemopexin domain of about 200 amino acids
(Figure 2b). Exceptions include MMP-7, MMP-23, and MMP-26, which lack the linker
peptide and hemopexin domain (Murphy and Nagase, 2008; Nagase et al., 2006). MMP23 uniquely contains a C-terminal cysteine rich immunoglobulin-like domain after the
catalytic domain (Gururajan et al., 1998; Park et al., 2000).
1.3

MMP regulation

Due to an overlap in substrate specificity, the biological function of an individual MMP
is often dictated by its differential pattern of expression as compared to other similar
MMPs (Sternlicht and Werb, 2001). Although expression varies during embryogenesis,
MMP transcription in healthy adult tissue is restricted to low levels, save for wound
healing or immune response, by a combination of inhibitory mechanisms (Moore and
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Crocker, 2012; Sternlicht and Werb, 2001). MMP expression can be influenced by a
variety of cytokines, growth factors, hormones, and chemical agents, leading to cell-type
specific responses (Mauviel, 1993). For example, transforming growth factor-β (TGF-β)
1 induces MMP-9 expression in oral squamous cell carcinoma (Sun et al., 2008). In
contrast, inhibition of TGF-β in mice following myocardial infarction results in increased
MMP-9 expression in ventricular myocardium (Frantz et al., 2008). Similar to
expression, which can be cell-type specific, growth factor responses can also be MMPspecific; some MMPs have a TGF-β1 inhibitory element in their promoter, whereas
others, like MMP-2, do not (Cui et al., 2017). In many cases, stimulatory or suppressive
factors modulate the expression/activation of c-fos and c-jun, which bind activator protein
(AP-1) sites within MMP promoters.
Additional to transcriptional regulation, like other proteolytic enzymes, MMPs are
synthesized as zymogens and are post-translationally regulated. The inhibitory prodomain of proMMPs is removed either intra- or extracellularly to expose the catalytic
domain. Membrane-type MMPs, as well as MMP-11, -21, -23, and -28, contain a target
sequence between the propeptide and catalytic domain, which is commonly cleaved by
furin in the trans-Golgi network (Pei and Weiss, 1995; Ra and Parks, 2007). Secreted
soluble MMPs that lack the furin-susceptible cleavage site are activated outside of the
cell by serine proteases and other MMPs. Treatment with heavy metals, oxidants,
disulfide compounds, and sulfhydryl-alkylating agents can also disrupt the inhibitory prodomain cysteine switch, thus uncovering the catalytic domain (Van Wart and BirkedalHansen, 1990).
In addition to pro-domain inhibition of proteolytic function, another level of MMP
regulation relies on compartmentalization of MMPs to specific regions of the pericellular
environment. Localization to the plasma membrane is straightforward for membrane-type
MMPs, but soluble MMPs can also be anchored to maintain a locally high concentration
at the cell surface. Protein-protein interactions that compartmentalize soluble MMPs
include MMP-1 to α2β1 integrin (Dumin et al., 2001; Stricker et al., 2001), MMP-2 to
αVβ3 integrin (Brooks et al., 1998) and MMP-9 to cluster of differentiation 44 (CD44)
(Yu and Stamenkovic, 2000). Many docking mechanisms have not been definitively
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proven, though it is likely that other secreted MMPs are localized in a similar manner
(Parks et al., 2004; Ra and Parks, 2007). Confinement of MMPs to the cell surface is also
important for pro-enzyme activation by other proteases and increased probability of
substrate proteolysis. Additionally, MMPs have a localization to the leading edge of
migrating and invading cells. Migrating human colon adenocarcinoma L-10 cells express
MT1-MMP and MMP-2 on their leading edges to remodel the gelatin substrate on which
they were seeded. This migration was ablated by treatment with BB-94, a broad-spectrum
inhibitor of MMP proteolytic function (Nabeshima et al., 2000). Similarly, MT1-MMP as
well as MMP-2 and MMP-9 concentrate at invadopodia, specialized actin-based
protrusions commonly associated with invasive tumour cells (Bowden et al., 1999;
Buccione et al., 2004; Chen, 1989; Clark and Weaver, 2008; Linder, 2007; Nakahara et
al., 1997).
A further mechanism of MMP regulation involves blocking proteolytic function by
endogenous inhibitors within the ECM. Tissue inhibitors of metalloproteinases (TIMP)
are a family of secreted proteins that include TIMP-1, -2, -3, and -4 in humans. The
TIMP N-terminal domain binds non-covalently to the active catalytic domain of MMPs,
thus inhibiting the proteolytic function of the latter. The C-terminal domain plays a role
independent of catalytic inhibition and can bind various ECM and cell-surface proteins to
regulate cell survival and migration (Moore and Crocker, 2012; Stetler-Stevenson, 2008;
Tuuttila et al., 1998). The four mammalian TIMPs are able to bind each of the 23
different MMPs, but with different efficacies (Bourboulia and Stetler-Stevenson, 2010).
This interaction occurs in a 1:1 ratio of TIMP:MMP, but depending on the stoichiometry
of these proteins in the ECM, TIMPs can either inhibit or activate MMPs (section 1.4.1).
Another endogenous inhibitor shown to negatively regulate MT1-MMP, MMP-2, and
MMP-9 proteolytic activity and/or expression is reversion-inducing cysteine-rich protein
with Kazal motifis (RECK), a GPI-anchored protein (Chang et al., 2008; Oh et al., 2001;
Simizu et al., 2005; Takahashi et al., 1998). The Kazal motifs, for which RECK is named,
are serine protease inhibitor-like domains believed to suppress MMP proteolytic function
(Takahashi et al., 1998). Interestingly, TIMP-2 can bind α3β1 integrin on the surface of
human endothelial cells leading to increased RECK expression, suggesting that these
inhibitors may act in a coordinated manner (Oh et al., 2004). While TIMPs and RECK
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are the most commonly studied endogenous inhibitors that reversibly bind MMPs, others
such as α2-macroglobulin can irreversibly clear MMPs from the ECM (Tchetverikov et
al., 2003). MMP•α2-macroglobulin complexes are removed by scavenger receptormediated endocytosis (Sternlicht and Werb, 2001). Altogether, MMP proteolytic activity
can be regulated by TIMPs, RECK, and other endogenous inhibitors, which too can differ
in their transcriptional regulation and tissue-specific expression patterns (Sternlicht and
Werb, 2001).
1.4

Membrane-type 1 matrix metalloproteinase

Membrane-type 1 matrix metalloproteinase (MT1-MMP) is the commonly used alias of
MMP14 employed by the broader scientific community. Of all MMPs, MT1-MMP is
well characterized due to its importance during development as well as many human
pathologies. MT1-MMP is indispensable for embryonic development as it is the only
MMP that is lethal when knocked out in mice (Holmbeck et al., 1999). These knockout
mice exhibit craniofacial dysmorphism, dwarfism, and arthritis due to an ablation in
collagenolytic activity crucial during skeletal and extraskeletal tissue development
(Holmbeck et al., 1999). As a collagenase, MT1-MMP can degrade integral ECM
substrates such as collagen types I, II, and III, as well as vitronectin and laminin 1
(Ohuchi et al., 1997). While MT1-MMP expression is common in development, it is low
or negligible in healthy adult cells. However, cancerous cells may reactivate the
developmental transcriptional programming of MMPs since MT1-MMP is present in
mesenchymal cancers, sarcomas, and mesotheliomas as well as primary human breast
cancers (Li et al., 2015; Lodillinsky et al., 2016; Marchesin et al., 2015; Turunen et al.,
2017). As there is no preeminent genetic link between MT1-MMP and cancer, this
suggests that the role(s) played by MT1-MMP in cancerous tissue is not due to a
mutation. For this reason, the extracellular proteolytic activity of MT1-MMP has been
well-studied due to its role in ECM remodelling during development as well as cell
migration and invasion. However, MT1-MMP functions on multiple levels: the
proteolysis of ECM molecules (section 1.4.1), MT1-MMP interaction with various
extracellular (section 1.4.2) and intracellular (section 1.4.3) binding partners, proteolysis
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of intracellular molecules (section 1.4.4), and as a possible transcription factor
(section1.4.5); as summarized in Figure 3 (Knapinska and Fields, 2019).
1.4.1 Proteolysis of ECM molecules
The most well-described proteolytic function of MT1-MMP is not related to degradation
of structural ECM molecules, but the activation of proMMP-2 in collaboration with
TIMP-2. As mentioned, MT1-MMP is embedded in the plasma membrane in an active
form with its pro-domain already removed. Two MT1-MMP molecules homodimerize
through their hemopexin and transmembrane domains (Itoh et al., 2001, 2008). A
TIMP-2 molecule can then bind via its N-terminal domain to the catalytic domain of one
of these MT1-MMP molecules, thus inhibiting its proteolytic activity (Strongin et al.,
1995). At this time, the hemopexin domain of a nearby proMMP-2, which has affinity for
the exposed TIMP-2 C-terminal domain, binds to it, forming a (MT1-MMP)2•TIMP-2•
proMMP-2 quaternary complex (Itoh and Seiki, 2006). The uninhibited MT1-MMP
within this complex is then able to cleave the pro-domain of MMP-2, initiating the
activation of this MMP-2 molecule (Will et al., 1996). Once activated, MMP-2 can either
be released into the ECM, remain bound to TIMP-2 via its hemopexin domain, or remain
bound to TIMP-2, but subsequently inhibited by another TIMP-2 molecule (Itoh et al.,
1998b). This activation mechanism is dependent on the precise stoichiometry of MMPs
and TIMP-2 in the ECM.
The significance of this mechanism of MT1-MMP-mediated MMP-2 activation is related
to their different enzymatic capabilities. MMP-2, but not MT1-MMP, is able to degrade
type IV collagen, a major component of the basement membrane (Okada et al., 1990).
This MT1-MMP/MMP-2 mediated cleavage of the basement membrane plays a role in
the growth and invasion of epithelial cancer cells in vivo (Taniwaki et al., 2007). It was
hypothesized that the sole function of MT1-MMP in tumour invasion was proMMP-2
activation (Ellerbroek and Stack, 1999; Seiki, 1999). However, MMP-2 deficient mice do
not show the same severe developmental defects as MT1-MMP null mice, suggesting
MT1-MMP has additional biological functions (Itoh et al., 1998a).

14
Figure 3. Domain-specific functions of membrane-type 1 matrix metalloproteinase
Research has identified key domains of MT1-MMP necessary for its proper structure,
localization, as well as various roles in ECM remodelling and cell signalling.
Simplistically, MT1-MMP is composed of an extracellular catalytic domain, a linker
region, and a hemopexin domain, followed by a transmembrane domain and intracellular
cytoplasmic tail. Altogether, the diverse functions of membrane-type 1 matrix
metalloproteinase are highlighted (Knapinska and Fields, 2019).
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MT1-MMP is not only involved in initiating cell movement through ECM degradation,
but also maintaining migration by cleaving ECM molecules that function as ligands in
cell signalling. When TGF-β is secreted, it is non-covalently associated with its latency
associated peptide, forming the small latent complex (SLC) (Miyazono et al., 1993).
Furthermore, the SLC needs to associate with the latent TGF-β binding protein (LTBP)
for proper secretion (Miyazono et al., 1991). Ultimately, MT1-MMP mediated cleavage
of TGF-β from LTBP plays a role in activating TGF-β signalling. MT1-MMP activation
of TGF-β1 has been associated with upregulation of CUTL1 and WNT5A to induce EMT
in prostate cancer cells (Nguyen et al., 2016). Furthermore, free TGF-β can increase the
expression of MT1-MMP, facilitating positive feedback via mothers against
decapentaplegic (SMAD) 3/4 induction of SNAIL in other cancer phenotypes (Ota et al.,
2009; Shields et al., 2011, 2012).
Additionally, MT1-MMP localization at the plasma membrane positions it to cleave
various other cell-surface molecules. For example, solubilization of extracellular matrix
metalloproteinase inducer (EMMPRIN) – a cell surface glycoprotein – by MT1-MMP not
only increases the expression/activation of other MMPs in surrounding cancerous cells,
but also from fibroblasts and stromal cells (Egawa et al., 2006; Sameshima et al., 2000).
MT1-MMP can shed other biomolecules such as fibronectin, death-receptor 6, protumour necrosis factor (Tam et al., 2004), syndecan-1 (Endo et al., 2003), E-cadherin
(Covington et al., 2006), various tetraspanins (Tomari et al., 2009), mucin 16 (Bruney et
al., 2014), and heparin-binding epidermal growth factor (Overland and Insel, 2015). All
of which have been associated with altered migration and invasion capabilities of
cancerous cells. Such observations have resulted in MT1-MMP being described as proinvasive and pro-migratory. However, MT1-MMP has also been shown to inhibit cancer
progression. MT1-MMP-mediated shedding of endoglin and lymphatic vessel endothelial
hyaluronan receptor-1 (LYVE-1) inhibits angiogenesis and lymphangiogenesis,
respectively (Hawinkels et al., 2010; Wong et al., 2016). Regardless, MT1-MMP
functions as a potent modulator of the pericellular environment through its proteolytic
activity.
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1.4.2 Extracellular binding partners
Although MT1-MMP has been implicated in cell migration, a well-defined mechanism
remains elusive since expression of constitutively inactive MT1-MMP still results in
increased cell migration (Bonnans et al., 2014; Hara et al., 2011). Recent focus has
shifted from the proteolytic to non-proteolytic functions of MT1-MMP with regards to
cell migration, specifically focusing on its hemopexin, transmembrane, and cytoplasmic
domains.
Migrating cells reorganize their actin cytoskeleton to form lamellipodia on the leading
edge, a process regulated by the Rho family of GTPases. These GTPases are also
involved in CD44 localization to lamellipodia, and by association MT1-MMP (Mori et
al., 2002; Ridley et al., 1992). In the context of CD44 - a hyaluronan receptor trafficking of MT1-MMP to the leading edge of migrating cells relies on the MT1-MMP
hemopexin domain binding to CD44 (Mori et al., 2002). Once localized to the leading
edge, MT1-MMP can degrade ECM molecules. Interestingly, the CD44•MT1-MMP
complex also activates EGFR. This crosstalk between CD44•MT1-MMP and EGFR
induces cell migration through mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K) pathways via phosphorylation of extracellular
signal-regulated kinase (ERK) 1/2 and AKT, respectively (Zarrabi et al., 2011). It has
been observed that MT1-MMP-mediated shedding of CD44 from the membrane is
important for enhanced cell migration (Kajita et al., 2001; Mori et al., 2002; Suenaga et
al., 2005). Shedding of CD44 disrupts its weak interaction with the substrate, eventually
being replaced with stronger integrin interactions that fortify migration (Cauwe et al.,
2007).
Binding of TIMP-2 to the MT1-MMP catalytic domain abolishes its proteolytic activity,
but TIMP-2 binding to the hemopexin domain promotes cell migration and tumour
growth via MAPK signalling (D’Alessio et al., 2008). The rat sarcoma (RAS) – rapidly
accelerated fibrosarcoma (RAF) – ERK1/2 cascade is induced by low, physiological
levels of TIMP-2, further highlighting the important stoichiometry of MMPs and their
inhibitors (D’Alessio et al., 2008; Yang et al., 2013). In contrast, another study observed
increased ERK1/2 activation when MT1-MMP was overexpressed in COS-7, which was
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ablated by exogenous TIMP-2 (Gingras et al., 2001). The cytoplasmic domain is involved
in ERK activation, but there is debate whether it is solely involved or works in
conjunction with the catalytic domain (D’Alessio et al., 2008; Gingras et al., 2001).
Regardless, in the context of its proteolytic and non-proteolytic functions, MT1-MMP
can associate with a variety of extracellular proteins that aid in ECM remodelling and
promote signalling.
1.4.3 Intracellular binding partners
There is conflicting evidence regarding influence of the MT1-MMP cytoplasmic domain
on protein-protein binding and its subsequent effects on cell migration, invasion, and
signalling. However, the dileucine motif (LL) within the cytoplasmic domain is important
for internalization of MT1-MMP through clathrin-dependent mechanisms. Caveolindependent internalization has also been observed (Jiang et al., 2001; Uekita et al., 2001).
Only 20 amino acids in length, the cytoplasmic tail does not contain sequences that
suggest any catalytic activities (Gingras et al., 2001). However, certain residues within
the MT1-MMP cytoplasmic tail can be post-transcriptionally modified, particularly
phosphorylation of Tyr573 and Thr567. Src-dependent phosphorylation of Tyr573 has
been shown to impact tumour cell migration and proliferation, but there is debate about
its effect on MT1-MMP catalytic activity (Nyalendo et al., 2007, 2008; Wang and
McNiven, 2012). Similarly, phosphorylation of Thr567 enhances invasion and growth of
breast and ovarian cancers (Moss et al., 2009; Yang et al., 2017). There is sequence
similarity between the cytoplasmic domain and integrin alpha subunits (Dedhar and
Hannigan, 1996; Gingras et al., 2001). Further links with integrins exist as during
mammary gland branching, the MT1-MMP cytoplasmic domain is believed to regulate
expression and activity of β1 integrin and subsequently control cell division (Mori et al.,
2013).
A characteristic of cancer cells is altered metabolism by increasing glycolysis even in the
presence of adequate oxygen, termed the Warburg Effect (Warburg, 1956). The MT1MMP cytoplasmic domain can impact cell survival in times of metabolic stress by
increased transcription of hypoxia-inducible factor (HIF)-1α target genes (Koziol et al.,
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2012; Sakamoto et al., 2011). During processing in the Golgi, the cytoplasmic domain
binds to factor-inhibiting HIF-1α (FIH), recruiting its inhibitor amyloid β A4 precursor
protein-binding family A member 3 (Mint3), thus deterring FIH-induced repression of
HIF-1α. Once stabilized, HIF-1α can alter the expression of multiple genes, most
importantly, glycolytic enzymes such as glucose transporter 1, hexokinase 2, lactate
dehydrogenase, and monocarboxylate transporter 4 (Hay, 2016). Under normoxic
conditions, FIH inhibits HIF-1α; it is typically only during hypoxia that FIH is negatively
regulated to shift cellular metabolism. However, MT1-MMP induces the Warburg Effect
even under normoxia in cancer cells to increase cell survival (Sakamoto et al., 2011).
Similarly, the cytoplasmic domain has also been shown to have a role in MCF-7 cell
survival when grown in serum-starved media (Cepeda et al., 2017b). While small, the
cytoplasmic domain is involved in MT1-MMP recycling, can be phosphorylated to
potentially facilitate cell signalling, and influences cellular metabolism via HIF-1α
activation.
1.4.4 Proteolysis of intracellular molecules
Several cell-based proteomic studies have suggested that the MT1-MMP catalytic domain
is involved in proteolysis of various intracellular substrates. Cleaved molecules include
enolase-β, enolase-γ, fructose-bisphosphate aldolase A, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and phosphoglycerate phosphokinase 1 (Cauwe and
Opdenakker, 2010). Degradation of these metabolic enzymes would stop glucose
metabolism at the fructose-1,6-bisphosphate (F1,6BP) stage. If stopped there, metabolism
would shift from oxidative phosphorylation to a different pathway such as glycogenesis,
again linking MT1-MMP function with metabolic regulation (Hay, 2016). Alternatively,
F1,6BP can activate Ras, ultimately linking glycolysis and cell proliferation (Peeters et
al., 2017). Apart from metabolism, MT1-MMP accumulates in the centrosome, where it
cleaves pericentrin, which coordinates the mitotic spindle (Golubkov et al., 2005), and
the breast cancer type 2 (BRCA1) susceptibility protein (Wali et al., 2014). Thus, as with
its well-described extracellular roles, MT1-MMP-mediated proteolysis of intracellular
proteins also impacts cell growth and survival.
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1.4.5 MT1-MMP as a transcription factor
The role of MT1-MMP as a transcription factor is speculative, but related to the fact that
active MT1-MMP and MMP-2 have been observed to colocalize in the nucleus (Ip et al.,
2007). The functional consequences of this localization are undetermined. However,
MT1-MMP is trafficked to nuclei in macrophages (Shimizu-Hirota et al., 2012). There it
putatively modulates the expression of over 100 genes through expression/activation of
the PI3Kδ/AKT/GSK3β signalling cascades. Many of these genes were linked to immune
regulation (Shimizu-Hirota et al., 2012). Evidence that MT1-MMP itself is a transcription
factor is nonexistent as associated changes in expression rely on its ability to facilitate
signalling cascades and secondary molecules that will eventually function as a
transcription factor. However, the reported presence of MT1-MMP in the nucleus
suggests interactions with yet to be identified binding partners.
1.5

MT1-MMP proteomic research

Several proteomic approaches have been used to study MT1-MMP protein-protein
interactions, with focus often on the investigation of proteolytic substrates. Earlier studies
identified these substrates by observation of degradation products following digestion
with a soluble MT1-MMP catalytic domain (Ohuchi et al., 1997). However, the use of
mass spectrometry technology has provided a high-throughput analysis of cellular
interactomes, especially protein-protein interactions. Although methodology changes
depending on the approach, protein-protein interaction studies typically use affinity
purification – mass spectrometry (AP-MS) (Vermeulen et al., 2008). In brief, a “bait”
protein (MT1-MMP, in this case) is purified from control and treatment samples
simultaneously with any “prey” proteins bound to it. Following purification, protein
samples undergo digestion into peptide fragments before mass spectrometry analysis.
Bottom-up proteomics relies on the resulting MS/MS spectra and bioinformatic tools to
identify the peptide sequence, and ultimately, the protein. Depending on the need to
quantify protein abundance between samples, proteins may be labelled for relative
comparison (Nesvizhskii, 2012). The below six studies have utilized mass spectrometry
to identify MT1-MMP substrates and binding partner.
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Unlabelled AP-MS was used to better understand the link between MMPs and
cardiovascular phenotypes commonly observed in animal models. A total of 15 proteins
were identified as vascular substrates in human plasma and 12 different proteins in
human radial arteries (Hwang et al., 2004; Stegemann et al., 2013). Both studies
identified degradation products by mass spectrometry through comparison of total protein
following incubation with catalytically active or inactive MT1-MMP. As several protease
inhibitors are cleaved by MT1-MMP, incubation with MT1-MMP may indirectly activate
other proteases; thus secondary cleavage products may be misinterpreted as MT1-MMP
substrates (Hwang et al., 2004). However, advances in technology have created new
MS-based approaches for the identification of MMP substrates.
Since mass spectrometry is not inherently quantitative, isotope-coded affinity tagging
(ICAT) is a MS technique that labels proteins with biotin-tagged reagents that differ in
isotopic composition analysis (Cauwe and Opdenakker, 2010). Using MDA-MB-231
breast cancer cells transfected with MT1-MMP, 17 proteins displayed altered abundance.
Interestingly, only two were typical ECM proteins whereas the others included protease
inhibitors, chemokines, cytokines, and cell receptors (Tam et al., 2004). Building upon
this, researchers investigated the proteome-wide effects of prinomastat, a broad-spectrum
MMP inhibitor. In particular, it was studied how treatment of prinomastat alters MMPmediated ECM degradation and membrane protein shedding (Butler et al., 2008). Over
40 novel substrates were identified within the study, 20 of which were validated
following incubation with soluble MT1-MMP. Dickkopft-1, pentraxin, thrombospondin,
cathepsin A/B, and galectin-3-binding protein were observed as novel MT1-MMP
substrates (Butler et al., 2008). However, intracellular proteins were not considered in
either of these studies.
Recent studies of MT1-MMP binding partners utilized similar ICAT techniques for
protein quantification, but affinity purify FLAG-tagged MT1-MMP and its binding
partners before mass spectrometry identification. Using this approach, 158 and 163
proteins were isolated with MT1-MMP in A375 melanoma (Tomari et al., 2009) and
A431 carcinoma cells (Niiya et al., 2009), respectively. In addition to identifying
previously known MT1-MMP substrates, non-substrate proteins were also observed and
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localized to the membrane, cytoplasm, or secretory pathway. This exemplifies the myriad
of possible partners and their localizations.
1.6

Objectives and hypothesis

MT1-MMP has multiple proteolytic and non-proteolytic functions that contribute to
proper development as well as pathological diseases. The studies described above utilized
mass spectrometry to identify binding partners of MT1-MMP that contribute to its
diverse functions. However, previous research used either soluble MT1-MMP domains to
identify substrates or correlate changes in expression, protein level, or cellular dynamics
after excessive MT1-MMP transfection; neither of which appear to be physiologically
relevant. In proteomic studies, the catalytic activity of MT1-MMP is inactivated through
amino acid substitution (Niiya et al., 2009; Tam et al., 2004; Tomari et al., 2009) or
exogenous inhibitors (Butler et al., 2008; Stegemann et al., 2013). For this reason,
studying MT1-MMP binding partners that may act as the source of diverse cellular
functions is an attractive route to better understand the proteolytic, but more specifically,
the non-proteolytic contributions of MT1-MMP. The aim of this study was to generate a
catalog of proteins that associate with MT1-MMP to corroborate previous research
regarding the role of MT1-MMP in cell migration, invasion, and survival. In a greater
scope, it is important to understand the basic mechanistic function, particularly with
respect to binding partners, of relevant proteases within the human degradome.
I hypothesize that if domains of MT1-MMP have different functions, then
individual domains will have different binding partners.
Human MCF-7 breast cancer cells were previously generated to either overexpress
MT1-MMP (C1) or express a truncated form of MT1-MMP lacking its cytoplasmic
domain (ΔCD). In this study, these cells were used to: 1) identify MT1-MMP binding
partners using a combination of co-immunoprecipitation and mass spectrometry, 2)
compare binding partners between full-length and truncated MT1-MMP expressing cells
to determine the role of the cytoplasmic domain in MT1-MMP function, and 3) assess
involvement of the cytoplasmic domain of MT1-MMP in cell signalling pathways to
better elucidate its role in cell migration.
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2

MATERIALS AND METHODS

2.1

Buffers and solutions

All solutions and buffers are dissolved in ddH2O unless otherwise specified.
2.1.1 Solutions
Phosphate Buffered Saline (PBS), pH 7.4: 154 mM NaCl, 1.05 mM KH2PO4, 5.6 mM
Na2HPO4
2.1.2 Buffers
Nonidet P-40 (NP-40) lysis buffer: 100 mM NaCl, 0.1% NP-40, 10% glycerol, 1 mM
ethylenediaminetetraacetic acid (EDTA), 50 mM Tris-HCl pH 8.0
Radioimmunoprecipitation assay (RIPA) lysis buffer: 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-HCl pH 8.0
SDS running buffer: 25 mM Tris, 192 mM glycine, and 0.1% SDS
Tris Buffered Saline with Tween 20 (TBST, pH 7.5): 50 mM Tris, 150 mM NaCl, 0.05%
Tween 20, pH 7.4
Transfer Buffer: 100 mM Tris, 191 mM glycine, 20% methanol
Antibody Stripping Buffer: 2 M glycine pH 2.3
2.2

Cell culture conditions

The human adenocarcinoma breast cancer cell line MCF-7 (ATCC® HTB-22™) was
donated by Dr. Postovit, University of Alberta. Cells were incubated at 37ºC with 5%
CO2 in Dulbecco’s Modified Eagle Medium (DMEM)/ F-12 media supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells
grown in serum-free conditions were maintained in DMEM/F-12 media containing only
1% penicillin/streptomycin. Cells were maintained below 80% confluency and passaged
accordingly using 0.25% Trypsin-EDTA (Gibco).
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Stable MCF-7 cell lines were previously created as follows by Dr. Mario Cepeda and
Jake Pelling (Cepeda et al., 2016, 2017b). MCF-7 cells were selected following
transfection with either full length MT1-MMP or truncated MT1-MMP with its
cytoplasmic domain removed. Populations were isolated, expanded, and assayed for
MT1-MMP expression and protein level using qPCR and immunoblotting, respectively.
Stable transfection of MCF-7 cells with full-length MT1-MMP created a cell line,
henceforth referred to as C1, with a ~2500-fold increase in expression in comparison to
MCF-7 parental cells (Cepeda et al., 2016). Transfection with MT1-MMP lacking its
cytoplasmic domain created a cell line with a ~100-fold increase in MT1-MMP
expression and produced a protein of lower molecular weight, henceforth referred to as
ΔCD (Cepeda et al., 2017b).
2.3

RNA analysis

2.3.1 RNA extraction and real-time PCR
Real-time PCR (qPCR) analysis was performed to determine mRNA transcript levels
between parental MCF-7, C1, and ΔCD cells. RNA was collected 24 hours after cells
were seeded at a density of 5 x 105 cells/mL using the RNeasy Mini Kit (Qiagen)
according to manufacturer’s instructions. RNA concentration and quality were
determined using a NanoDrop2000 spectrophotometer (Thermo Fisher Scientific). cDNA
was synthesized from 1 μg RNA using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) according to manufacturer’s instructions. Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression was used as an internal control
(Cepeda et al., 2016). cDNA was amplified using primers (sequences provided in Table
1) as well as quantified using SensiFAST SYBR (Bioline) and a CFX96 Real-Time PCR
Detection System (BioRad). qPCR was conducted at 95ºC for 2 minutes, followed by a
repeated reaction schedule of denaturation at 95ºC for 5 seconds, primer annealing at
60ºC for 10 seconds, and primer extensions at 72ºC for 20 seconds. Transcript levels
were calculated and normalized to the internal control. Gene expression relative to
parental MCF-7 cell transcript was calculated using the ΔΔCt method (Livak and
Schmittgen, 2001).

Table 1. Primer sequences used for qPCR.
Forward (5’ → 3’)

Reverse (5’ → 3’)

BSG

GGCTGTGAAGTCGTCAGAACAC

ACCTGCTCTCGGAGCCGTTCA

BST2

GCATGTGCTGCCTGTTGTTAT

TCAGGTGTGCTCTCCCTCAA

CDC42

TAACTCACCACTGTCCAAAGACTC

CCTCATCAAACACATTCTTCAGACC

CDH1

GCCGCTGGCGTCTGTAGGAA

TGACCACCGCTCTCCTCCGA

CDKN1A

GGGCTGGGAGTAGTTGTCTT

ACAGGAGCTGGAAGGTGTTT

EHF

GCACAACGGCACAACCTTC

TGACTTGTGGAACCCAACGG

GAPDH

ACCCACTCCTCCACCTTTGA

CTGTTGCTGTAGCCAAATTCGT

ITGB1

GAAGGGTTGCCCTCCAGA

GCTTGAGCTTCTCTGCTGTT

MMP14

GCAGAAGTTTTACGGCTTGCA

TCGAACATTGGCCTTGATCTC

SLC39A1

GCCTACCCCCAGCGTTATTT

ACAGGTCCCAAAACAGGTCA

SMAD2

TGCACACATCTACACTGGCT

TGAGGGGTGGGGATGGTATT

SMAD4

GTAGAGGCCAGCTTTGTGGT

AATCAATCCAAGCCCGTGAGT

SNAI1

AGGGACTGTGAGTAATGGCTG

AGTTCTGGGAGACACATCGG

TGFB1

TTATTGAGCACCTTGGGCACT

TGGGCTTGTTTCCTCACCTTT

TGFB2

CTATGTTCTGCCAACGCCAG

AACCAACCCCAGAAAGCACG

TGFB3

AGACCCTGTGTTCATTTGGTGT

TACCTCAGTCTATGCGTCTGG

TGFBR1

TCTGTTGCCTTTGGGTCAGC

AATCAAGGGTTTGGGGACCA

TGFBR2

TGTGGGTGGGCTGAGAGTTA

AGAGGTCAATGGGCAACAGC
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Gene

(Table 1 continued)
Gene

Forward (5’ → 3’)

Reverse (5’ → 3’)

TGFBR3

CGCGTGCCAGTCTTTTTGTA

TCACATAGGACTCACCCAACA

TP53INP1

TATAGGGGCAGGGCATGAGT

CGAGAAACACATTAAGAAGGCACA
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2.4

Protein analysis

2.4.1 Protein collection and immunoblotting
Immunoblotting was performed to assay for changes in protein level between cell lines.
Cells were seeded at a density of 5 x 105 cells/mL. Twenty-four hours later, cells were
washed with PBS and disrupted using RIPA lysis buffer supplemented with
phosphatase/protease inhibitor cocktail (Thermo Scientific). Collected protein lysates
were shaken on ice for 20 minutes and sonicated three times for 10 seconds each. Protein
concentration was quantified using a Pierce bicinchoninic acid (BCA) Protein Assay Kit
(Thermo Scientific). Either 10 or 20 μg of protein per sample was mixed with the
appropriate amount of Laemmli sample buffer (BioRad) and subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS PAGE) at 130 V for approximately three
hours in SDS running buffer. Protein was transferred to a polyvinylidene difluoride
(PVDF) membrane (BioRad) overnight at 4ºC using 12 V. Membranes were then blocked
in either 0.5% or 5% bovine serum albumin (BSA) (Fischer Scientific) dissolved in
TBST for 30 minutes at room temperature. Blots were subsequently incubated overnight
at 4ºC with a primary antibody (section 2.4.3) followed by an appropriate secondary
antibody for one hour at room temperature. Blots were analyzed using a ChemiDoc™
Imaging System (BioRad) and quantified using Image Lab (BioRad) software.
2.4.2 Immunoblot densitometry analysis
Chemiluminescence was analyzed using a ChemiDoc™ Imaging System (BioRad) and
Image Lab software (BioRad). Band intensity of a protein of interest was quantified and
normalized to β-actin using three independent biological samples (Cepeda et al., 2016).
TGF-β1 SLC protein level was shown as a ratio of TGF-β1 SLC signal standardized to
β-actin before comparison to parental MCF-7. SMAD2 activation is presented as a ratio
between the phospho-SMAD2 and total SMAD2 band intensities within each sample
normalized to parental MCF-7 cells.
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2.4.3 Antibodies
The following antibodies were used: mouse anti-MT1-MMP (1:200, sc-377097, Santa
Cruz), rabbit anti-MT1-MMP (1:1000, AB6004, Millipore), rabbit anti-MT1-MMP
(1:2000, ab51074, Abcam), rabbit anti-TGF-β1 (1:2000, ab92486, Abcam), rabbit antihyaluronan-mediated motility receptor (HMMR) (1:200, ab124729, Abcam), mouse antivitronectin (1:250, ab13413, Abcam), rabbit anti-fragile X mental retardation 1 (FMR1)
(1:200, ab17722, Abcam), rabbit anti-phosho-SMAD2 (1:1000, 138D4, Cell Signaling
Technology), mouse anti-SMAD2 (1:1000, 610843, BD Transduction Laboratories),
mouse anti-β-actin (1:1000, sc-47778, Santa Cruz), and normal rabbit immunoglobulin G
(IgG) control (AB-105-C, R&D Systems). Following primary antibody incubation, goat
anti-mouse IgG (H+L) (BioRad) and goat anti-rabbit IgG (H+L) (Invitrogen) horseradish
peroxidase (HRP) conjugates were used as secondary antibodies for immunoblot analysis
(1:10 000). Clarity™ Western Enhanced Chemiluminescence Substrate (BioRad) was
used according to manufacturer’s instructions to detect secondary antibody.
The MT1-MMP antibody (ab51074) used for immunoprecipitation recognizes the
extracellular region of MT1-MMP. Thus, MT1-MMP lacking its cytoplasmic domain was
efficiently isolated.
2.4.4 Immunoprecipitation
Immunoprecipitation was used to isolate MT1-MMP and its binding partners in MCF-7,
C1, and ΔCD cell lines. Cells were seeded at a density of 4 x 105 cells/mL in a 60 mm
cell culture dish and incubated for twenty-four hours. On ice, cells were washed with cold
PBS before lysate was collected using NP-40 lysis buffer supplemented with
phosphatase/protease inhibitor cocktail (Thermo Scientific). Protein lysate was shaken on
ice for 20 minutes, homogenized using a 20G syringe, and quantified using a Pierce BCA
Protein Assay Kit (Thermo Scientific). Aliquots containing 100 μg of protein were
incubated with rabbit anti-MT1-MMP (ab51074) at 25:1 v/v ([ab51074] is 0.174 mg/ml).
In parallel, aliquots of 100 μg of protein were incubated with the same volume of rabbit
IgG antibody as a negative control. SureBeads Protein A Magnetic Beads (BioRad) were
used according to manufacturer’s instructions to precipitate the antibody complexes.
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Following immunoprecipitation, proteins were eluted from beads with either Laemmli
sample buffer for immunoblotting analysis of MT1-MMP and its binding partners, or
200 mM glycine (pH 2.0) for in-solution digestion and subsequent mass spectrometry
analysis. To prevent detection of heavy and light IgG chains of the primary antibody used
to immunoprecipitate MT1-MMP, rabbit anti-MT1-MMP was used to immunoprecipitate
whereas mouse anti-MT1-MMP was used in immunoblot analysis.
2.4.5 In-solution trypsin digestion
Following immunoprecipitation of MT1-MMP from protein lysate, coimmunoprecipitation eluent underwent in-solution digestion before mass spectrometry
analysis. Beads used to precipitate MT1-MMP protein complexes were incubated with
200 mM glycine (pH 2.0) for fifteen minutes in a thermoshaker at 56ºC and 400 rpm
before neutralization with Tris-HCl (pH 8.0). Samples were reduced with 10 mM
dithiothreitol (DTT; dissolved in 100 mM NH4HCO3) for one hour at room temperature.
Following reduction, samples were alkylated using 100 mM iodoacetamide (dissolved in
100 mM NH4HCO3) for one hour at room temperature in the dark. Protein was
precipitated with trichloroacetic acid (TCA) extraction, resuspended in 50 mM NH4HCO3
(pH 7.8), and quantified using a spectrophotometer (NanoDrop 2000, Thermo Scientific)
and protein standards. Samples were then subjected to in-solution digestion with 2%
(w/w) sequencing-grade trypsin (Thermo Scientific; resuspended in 50 mM NH4HCO3)
for 18 hours at 37ºC and 700 rpm. Additionally, 1% (w/w) trypsin was added for 4 hours
at 37ºC and 1400 rpm. Resulting peptide samples were purified and concentrated using
C18 Spin Columns (Thermo Scientific) according to manufacturer’s instructions. Peptide
samples were quantified, lyophilized, and resuspended in 0.1% formic acid before
analysis by liquid chromatography-tandem mass spectrometry.
2.4.6 Liquid chromatography-tandem mass spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of 3 biological
replicates from each cell line were carried out at the Don Rix Protein Identification
Facility, Department of Biochemistry (UWO). Every mass spectrometry run included
samples immunoprecipitated with an MT1-MMP antibody, identical samples
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immunoprecipitated with a rabbit IgG antibody (negative control), as well as a BSA
solution that underwent in-solution digestion (positive control). Samples were separated
using an ACQUITY UPLC M-Class system (Waters Corporation) connected to an
Orbitrap Elite Mass Spectrometer (Thermo Fisher Scientific). Buffer A consisted of
water/0.1% formic acid and buffer B consisted of acetonitrile/0.1% formic acid. Samples
were trapped for 6 minutes at a flow rate of 5 μL/min using 99% buffer A and 1% buffer
B on an ACQUITY UPLC M-Class Symmetry C18 Trapping Column (100 Å, 5 μm,
180 μm x 20 mm, Waters). After trapping, peptides were separated using an ACQUITY
UPLC M-Class Peptide BEH C18 Column (130 Å, 1.7 μm, 75 μm x 250 mm) operating
at a flow rate of 300 nL/min at 35°C using a 5-40% acetonitrile gradient over 90 minutes.
An Orbitrap Elite Mass Spectrometer recorded the mass-to-charge ratio (m/z) of ions over
the range of 380-1600. The mass spectrometer was controlled by Xcalibur™ software
(Thermo Fisher Scientific) and operated in the data-dependent mode using FT/IT/CID
Top 10 scheme.
2.4.7 Protein Identification
Data analysis was performed using PEAKS Studio 10.0 (Bioinformatics Solutions Inc.).
MS/MS spectra were searched against the Human Uniprot database with trypsin
specificity (updated January 2019 with 20 380 entries; UniProt Consortium, 2019).
Missed cleavages were set to 3. Cysteine carbamidomethylation was set as a fixed
modification, whereas oxidation (M) and deamidation (NQ) were set as variable
modifications (max number of modifications per peptide = 5). All other PEAKS Studio
software settings were left as default. Peptide and protein false discovery rate (FDR) was
set to 1% (Hughes et al., 2012). FDR values were calculated using the Decoy-Fusion
method in PEAKS. Proteins identified by a minimum of one unique peptide and isolated
in ≥ 2 biological replicates were retained for downstream analysis (Kuljanin et al., 2017),
unless otherwise specified. Proteins identified following rabbit IgG pulldown were
considered non-specific background proteins and subsequently removed from the MT1MMP co-immunoprecipitation datasets. Additionally, structural components of the
ribosome and spliceosome were removed. Immunoprecipitation followed by immunoblot
analysis was used to confirm selected complexes detected by LC-MS/MS as described in
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sections 2.4.1 and 2.4.2. Antibodies specific to hyaluronan mediated motility receptor
(HMMR), fragile X mental retardation 1 (FMR1), and vitronectin (VTN) were used to
validate mass spectrometry results.
Following PEAKS analysis, the Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) was used to create protein-protein interaction (PPI) networks.
STRING (version 11.0) is a well-known public database of protein associations that
covers 19 566 protein coding genes from Homo sapiens (NCBI taxon ID: 9606)
(Szklarczyk et al., 2019). Proteins identified by mass spectrometry were mapped via
STRING using co-expression analysis, pathway knowledge from curated databases, and
experimentally validated associations (confidence = 0.4). Cytoscape software
(version 3.7) was used to construct a PPI network. Within a PPI network, Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to identify
enrichment of pathway-specific genes within the network. KEGG is a manually curated
database resource with a collection of pathway maps integrating many aspects of the
biological system (genes, proteins, RNAs, etc.).
2.5

Statistics

Statistical analysis and graphing of qPCR and immunoblot data was performed using
Microsoft Excel (Office 365). Data is present as mean ± SEM. Means were compared
using one-way ANOVA followed by Tukey’s post-hoc test. Levels of statistical
significance are as follows: ****, p ≤ 0.0001; ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.
KEGG pathway analysis enrichment scores are presented as FDR.
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RESULTS

In this study, MCF-7 cell lines were used to: 1) identify MT1-MMP binding partners, 2)
compare binding partners isolated from full-length and truncated MT1-MMP expressing
cells, and 3) assess the involvement of the MT1-MMP cytoplasmic domain in cell
signalling. Objectives 1 and 2 identified MT1-MMP binding partners that alluded to the
role of the cytoplasmic domain on MT1-MMP function. In parallel with proteomic
experiments, a different approach was used in Objective 3 to identify changes in
expression and protein level between the cell lines. This was done to corroborate previous
research that observed an increase in ΔCD, but not C1, cell migration relative to parental
MCF-7 cells (Cepeda et al., 2016, 2017b).
3.1

Stable MCF-7 cell lines, C1 and ΔCD, have altered expression of
MT1-MMP

Cell lines used were repeatedly tested via qPCR and immunoblotting to ensure consistent
levels of MT1-MMP over the course of this study. MCF-7 cells were previously
transfected with either full length MT1-MMP (Cepeda et al., 2016) or MT1-MMP
lacking its cytoplasmic domain (Cepeda et al., 2017b). Parental MCF-7 cells have low
abundance of MT1-MMP transcript and did not show any detectable levels of MT1-MMP
protein (Figure 4). C1 cells created to have a ~2500-fold increase (p<0.0001) in
MT1-MMP produced a 63 kDa band as expected (Figure 4). The ΔCD cell lines, which
expresses ~100-fold increase (p<0.001) of MT1-MMP lacking its cytoplasmic domain
produced a corresponding smaller (59 kDa) band as expected (Figure 4).
3.2

Immunoprecipitation of MCF-7, C1, and ΔCD cell line lysates with antiMT1-MMP antibody isolated 248 unique proteins

To identify MT1-MMP binding partners, protein lysate from each cell line was
immunoprecipitated with an MT1-MMP antibody. The resulting precipitated complexes
were subsequently analyzed with mass spectrometry. As a negative control, cell lysates
were immunoprecipitated with a normal rabbit IgG antibody to identify any non-specific
antibody interactions. Due to the nature of ultra-sensitive mass spectrometry, these nonspecific proteins were removed. Additionally, components of the ribosome were also
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Figure 4. Stable transfection of MCF-7 cell lines produce different MT1-MMP
expression profiles.
(a) Average expression level of MT1-MMP from qPCR analysis of parental MCF-7, C1,
and ΔCD cell lines. Relative to parental MCF-7 cell expression, C1 MT1-MMP
expression is increased 2529-fold (p≤0.0001) whereas ΔCD is increased 83-fold
(p≤0.001). Log2 transformed mean fold change ± SEM is presented and was compared
using one-way ANOVA and Tukey’s post-hoc test; ****, p ≤ 0.0001; ***, p ≤ 0.001
(n=4). (b) Immunoblot analysis of parental MCF-7, C1, and ΔCD cell lysate show
different levels of MT1-MMP protein level. MT1-MMP protein cannot be visualized by
immunoblotting in MCF-7 cells, however, stable transfection of full-length MT1-MMP in
C1 cells showed a band corresponding to MT1-MMP (63 kDa). ΔCD MT1-MMP
transfection results in an increase of MT1-MMP protein, but at a lower molecular weight
due to the truncated protein (59 kDa). β-actin was used as a loading control.

34

a.

b.
MCF-7

mRNA fold change (log2 transformed)

14
12

C1
***

****

****

10
8
6
4
2
0
-2
MT1-MMP

ΔCD

MCF-7

C1

ΔCD

MT1-MMP

62 kDa

β-Actin

40 kDa

35

removed due to their overabundance in the rabbit IgG pulldown. Next, a protein was
considered a valid binding partner if it was identified by a minimum of one unique
peptide and observed in ≥ 2 biological replicates. Prior to filtering and removal of nonspecific proteins, 939 proteins were identified in MCF-7 cells, 919 proteins in C1 cells,
and 1051 proteins in ΔCD cells following immunoprecipitation with an MT1-MMP
antibody (Figure 5a). Following removal of non-specific proteins that were pulled down
with the MT1-MMP antibody as well as the rabbit IgG antibody, the catalog of MT1MMP binding partners was subjected to KEGG analysis.
KEGG analysis identified an enrichment of proteins associated with various pathways.
Sorted by FDR, the top 10 enriched pathways and their identified proteins are listed
(Appendix A). The pathways include: spliceosome (hsa03040), RNA transport
(hsa03013), RNA degradation (hsa03018), mRNA surveillance pathway (hsa03015),
protein processing in the endoplasmic reticulum (hsa04141), pathogenic Escherichia coli
infection (hsa05130), Huntington’s disease (hsa05016), endocrine and other factorregulated calcium reabsorption (hsa04961), non-homologous end-joining (hsa03450),
hepatocellular carcinoma (hsa05225), and endocytosis (hsa04144) (Appendix A).
Similarly, KEGG analysis of proteins pulled down with the control anti-rabbit IgG
identified enrichment in various pathways including the spliceosome (11 of 130 genes,
FDR=0.0145; data not shown). Due to the nature of spliceosomal-related proteins having
a unique, sometimes solely known function, these proteins were considered background
proteins. Therefore, 19 protein were removed from the pool of binding partners.
Following the removal of all non-specific proteins, the final dataset contained 200
proteins isolated in MCF-7 cells, 168 proteins isolated in C1 cells, and 70 proteins
isolated in ΔCD cells; a reduction of 79%, 82%, and 93%, respectively, from the original
dataset (Figure 5a). When proteins isolated in each cell line were compared, a total of 248
unique proteins immunoprecipitated with MT1-MMP in MCF-7, C1, and ΔCD cells
(Figure 5b, Appendix B). STRING analysis of the 248 proteins generated a proteinprotein interaction network of 224 nodes (proteins) and 1116 edges (protein-protein
interactions; data not shown). Subsequent KEGG pathway analysis of the catalog
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Figure 5. Total number of proteins immunoprecipitated with MT1-MMP in
parental MCF-7, C1, and ΔCD cell lines.
(a) A total of 939 proteins were identified in parental MCF-7 cells, 919 proteins in C1
cells, and 1051 proteins in ΔCD cells following immunoprecipitation with an MT1-MMP
antibody. Following removal of non-specific proteins, 200 proteins were identified as
true MT1-MMP interactions in parental MCF-7 cells, 168 protein in C1 cells, and 70
proteins in ΔCD cells. (b) Upon comparison of proteins isolated in each cell line, a total
of 248 unique proteins immunoprecipitated with MT1-MMP. A complete list of proteins
can be found in Appendix B.

37

a.
Parental MCF-7

ΔCD

C1

200

70

168

739

751

981

Non-specific proteins
removed

True MT1-MMP–protein
interactions

b.
Parental
MCF-7
74

C1
60

43

59
5

5
2
ΔCD

38

of 248 proteins identified enrichment in pathways including: RNA transport, RNA
degradation, mRNA surveillance pathway, protein processing in the endoplasmic
reticulum, Huntington’s disease, endocrine and other factor-regulated calcium
reabsorption, adrenergic signaling in cardiomyocytes (hsa04261), non-homologous endjoining, hepatocellular carcinoma, and endocytosis (Table 2).
3.3

Select MT1-MMP binding partners identified by mass spectrometry are
validated with immunoblotting

Select proteins identified by mass spectrometry were validated with immunoblotting
following immunoprecipitation with an MT1-MMP antibody. Elution of proteins from
magnetic beads with Laemmli buffer also elutes the immobilized antibody bound to the
beads. As a result, Western blot bands corresponding to the antibody heavy (50 kDa) and
light (25 kDa) polypeptide chains appear regardless of primary antibody species due to
cross-reactivity. For this reason, mass spectrometry identified proteins that were chosen
to be validated had a molecular weight greater than 60 kDa to be accurately visualized.
The proteins selected include hyaluronan mediated motility receptor (HMMR), fragile X
mental retardation 1 (FMR1), and vitronectin (VTN). As expected, proteins bands
corresponding to MT1-MMP were observed in MCF-7 and C1 cell lysate following antiMT1-MMP immunoprecipitation (Figure 6). Due to oversaturation of the immunoglobin
heavy chain chemiluminescent signal (50 kDa), membranes were trimmed at ~60 kDa.
As a result, MT1-MMP was poorly visualized in ΔCD cell lysate due to its lower
molecular weight (59 kDa). In agreement with HMMR and FMR1 being identified as
putative MT1-MMP binding partners by mass spectrometry, bands corresponding to
HMMR (84 kDa) and FMR1 (80 kDa) were observed in all cell lysates following antiMT1-MMP immunoprecipitation, but not rabbit IgG pulldown. While vitronectin was
identified by mass spectrometry as a putative binding partner MCF-7 and C1 cells, VTN
(62 kDa) was only identified in MCF-7 cell lysate following anti-MT1-MMP
immunoprecipitation.

Table 2. Top 10 most significantly enriched KEGG pathways represented by 248 proteins co-immunoprecipitated with
MT1-MMP from MCF-7, C1, and ΔCD cell linesa.
Sizeb

Genes

FDRa

RNA transport (hsa03013)

18

159

CASC3
EIF3I
FXR2
RAN

EIF2S1
EIF4A1
NUP210
SEC13

EIF2S3
EIF4G1
PABPC1
UPF1

EIF3C
FMR1
PABPC4

EIF3CL
FXR1
PNN

1.61 x 10-9

RNA degradation
(hsa03018)

11

77

CNOT1
EDC4
XRN2

CNOT2
HSPA9

CNOT3
HSPD1

CNOT7
PABPC1

DDX6
PABPC4

1.1 x 10-6

mRNA surveillance
pathway (hsa03015)

11

89

CASC3
PABPC4
WDR33

CPSF1
PNN

CPSF2
PPP1CA

FIP1L1
PPP1CC

PABPC1
UPF1

2.85 x 10-6

Protein processing in the
endoplasmic reticulum
(hsa04141)

12

161

BAG2
DNAJA1
HSP90AB1 HSPA1A
SEC13
SSR1

DNAJA2
HSPA5

EIF2S1
RPN1

HSP90AA1 8.25 x 10-5
RRBP1

Pathogenic Escherichia coli
infection (hsa05130)

7

53

CTNNB1
YWHAQ

NCL
YWHAZ

TUBB2A

TUBB2B

TUBB6

0.00033

Huntington’s disease
(hsa05016)

10

193

AP2A1
ATP5C1

AP2B1
CLTC

AP2M1
DCTN1

ATP50
NDUFA4

ATP5A1
SLC25A5

0.0071

Endocrine and other factorregulated calcium
reabsorption (hsa04961)

5

47

AP2A1

AP2B1

AP2M1

ATP1A1

CLTC

0.0118
39

Countb

ID: KEGG Pathway

(Table 2 continued)
Count

Size

Genes

Adrenergic signaling in
cardiomyocytes (hsa04261)

8

139

ATP1A1
PPP1CC

ATP2A2
TPM1

CALM1
TPM3

Non-homologous endjoining (hsa03450)

3

13

PRKDC

XRCC5

XRCC6

Hepatocellular carcinoma
(hsa05225)

8

163

ACTL6A
ARID2
CTNNB1
KEAP1
SMARCA4 SMARCC2 SMARCE1

PBRM1

0.0229

Endocytosis (hsa04144)

10

242

AP2A1
CAPZB

CAPZA
TFRC

0.0229

ID: KEGG Pathway

FDR

AP2B1
CLTC

AP2M1
HSPA1A

GNAI3

PPP1CA

0.0118
0.0187

ARF5
RAB10

a

Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate

b

Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway
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Figure 6. Validation of putative MT1-MMP binding partners HMMR, FMR1, and
VTN.
Lysates from parental MCF-7, C1, and ΔCD cell line were collected, immunoprecipitated
with an MT1-MMP antibody, and immunoblotted to confirm pulldown of proteins
identified by mass spectrometry. Hyaluronan mediated motility receptor (HMMR),
fragile X mental retardation 1 (FMR1), and vitronectin (VTN) were identified by mass
spectrometry to co-immunoprecipitate with MT1-MMP. HMMR and FMR1 were
identified in MCF-7, C1, and ΔCD cells whereas VTN was found in MCF-7 and C1
(Appendix B). In parallel, samples were immunoprecipitated with either a rabbit
MT1-MMP (IP:MT1-MMP) or normal rabbit IgG (IP: IgG) antibody followed by
Western blot analysis. Bands corresponding to HMMR (84 kDa) and FMR1 (80 kDa)
were observed in all cell lines. MT1-MMP (63 kDa) protein was visualized in MCF-7
and C1 lysate. Since membranes are trimmed at 60 kDa to limit oversaturation of the
heavy chain IgG chemiluminescent signal, the truncated form (59 kDa) of MT1-MMP
could not be visualized in ΔCD cell lysate. VTN (62 kDa) was observed only in MCF-7
cells. Pulldown with a rabbit IgG antibody showed no bands corresponding to HMMR,
FMR1, MT1-MMP, or VTN protein when probed with their respective antibodies.
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3.4

Proteins immunoprecipitated from full-length MT1-MMP expressing cell
lines, but not ΔCD, are involved in various KEGG pathways

Towards identifying any functional consequences of MT1-MMP lacking its cytoplasmic
domain, KEGG analysis was used to compare proteins isolated solely in cells expressing
full-length MT1-MMP (MCF-7 and C1) with those isolated in ΔCD. The premise of this
comparison was to identify potential cytoplasmic binding partners that may be important
for cell signalling or MT1-MMP localization that would be absent in ΔCD. A total of 177
proteins were identified following immunoprecipitation of MT1-MMP in MCF-7, C1, or
both cell lines in comparison to 71 proteins identified in ΔCD (Figure 5b). KEGG
analysis of proteins isolated in MCF-7 and C1 identified enrichment in various pathways
(Table 3) such as: protein processing in the ER, RNA degradation, mRNA surveillance,
RNA transport, pathogenic E. coli infection, non-homologous end-joining, protein export
(hsa03060), Huntington’s disease, adrenergic signaling in cardiomyocytes, and
endocytosis. Except for protein export, these pathways were enriched following KEGG
analysis of the original 248 proteins isolated with MT1-MMP pulldown (Table 2).
Conversely, KEGG analysis of proteins isolated from ΔCD identified an enrichment of
proteins related to RNA transport (7 of 159 genes; FDR=1.3 x 10-4; data not shown).
Therefore, enrichment identified in the 248-protein dataset is dependent on the proteins
isolated from full-length MT1-MMP expressing cells, and not ΔCD. Marked proteins (*)
within the table will be discussed later (section 4.4).
3.5

ΔCD cells have reduced TGF-β1 expression, but not small latency
complex protein level

A fundamental embryonic process that can be modulated by MT1-MMP activity is the
epithelial-mesenchymal transition. An objective of this research was to assess the
involvement of the MT1-MMP cytoplasmic domain in cell signalling pathways to better
elucidate its role in cell migration. To determine if expression of genes involved in EMT
differed between the cell lines, total RNA was extracted from each cell line to compare
transcript levels. Many of the EMT-associated genes chosen, Snail (SNAI1), cell division
cycle 42 (CDC42), cadherin 1 (CDH1), integrin subunit β 1 (ITGB1), and extracellular
matrix metalloproteinase inducer (BSG), did not differ between parental MCF-7 cells and

Table 3. Top 10 most significantly enriched KEGG pathways represented by 177 proteins co-immunoprecipitated solely with
full-length MT1-MMP expressing cells – MCF-7 and C1a.
Countb

Sizeb

Genes

Protein processing in the
endoplasmic reticulum
(hsa04141)

11

161

BAG2
DNAJA1
HSP90AB1 HSPA5
SSR1*

DNAJA2
RPN1*

EIF2S1
RRBP1

HSP90AA1 3.61 x 10-5
SEC13*

RNA degradation (has03018)

8

77

CNOT1
HSPA9

CNOT2
HSPD1

CNOT3
XRN2

CNOT7

EDC4

3.61 x 10-5

mRNA surveillance pathway
(has03015)

9

89

CASC3
PPP1CA

CPSF1
PPP1CC

CPSF2
UPF1

FIP1L1
WDR33

PNN

3.61 x 10-5

RNA transport (has03013)

11

159

CASC3
EIF4A1
UPF1

EIF2S1
NUP210

EIF2S3
PNN

EIF3C
RAN

EIF3CL
SEC13

3.61 x 10-5

Pathogenic Escherichia coli
infection (has05130)

6

53

CTNNB1
YWHAZ

NCL

TUBB2A

TUBB2B

TUBB6

0.00045

Endocrine and other factorregulated calcium reabsorption
(has04961)

5

47

AP2A1

AP2B1

AP2M1

ATP1A1

CLTC

0.0026

Non-homologous end-joining
(has03450)

3

13

PRKDC

XRCC5

XRCC6

0.0083

Protein export (has03060)

3

23

HSPA5

SRP14*

SRP72*

0.0314

ID: KEGG Pathway

FDRa
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(Table 3 continued)
ID: KEGG Pathway

Count

Size

Genes

FDR

Huntington’s disease
(has05016)

7

193

AP2A1
DCTN1

AP2B1
NDUFA4

AP2M1

ATP50

CLTC

0.0326

Adrenergic signaling in
cardiomyocytes (has04261)

6

139

ATP1A1
TPM1

ATP2A2

GNAI3

PPP1CA

PPP1CC

0.0326

Endocytosis (has04144)

8

242

AP2A1*
CLTC*

AP2B1*
RAB10*

AP2M1
TFRC

ARF5

CAPZB

0.0326

a

Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate

b

Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway

* proteins are discussed in Chapter 4
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C1 or ΔCD (Figure 7a). However, a 5-fold reduction of TGFB1 expression was observed
in the ΔCD line (p≤0.05), but not in the C1 cell line. Immunoblot analysis determined
that the reduction of TGFB1 expression in ΔCD cells did not result in a decrease in
TGF-β1 protein. Bands corresponding to TGF-β1 small latency complex (44 kDa) were
quantified with no significant difference observed between cell lines (Figure 7b).
Quantification of secreted TGF-β1 in media using protein precipitation and
immunoblotting was unsuccessful.
3.6

ΔCD cells have altered expression of TGFβ subfamily members and
increased SMAD2 phosphorylation

To better understand the decrease of TGFB1 RNA levels in ΔCD cells, the expression of
other TGF-β family members was quantified. In contrast to a decrease of TGFB1
expression, ΔCD cells had increased levels of TGFB2, TGFB3, and TGFBR3 (p<0.05) in
comparison to parental MCF-7 cells (Figure 8a). No change in expression of TGF-β
isoforms or receptors was observed in C1 cells relative to parental MCF-7 cells. Since
TGF-β1 and TGF-β2 share similar activation mechanisms of TGF-β signalling through
the canonical SMAD pathway, levels of SMAD2 phosphorylation was quantified. Protein
bands corresponding to phospho-SMAD2 (60 kDa) were quantified relative to total
SMAD2 levels (58 kDa). ΔCD cells displayed a 3.5-fold increase in SMAD2
phosphorylation relative to parental MCF-7 cells, with no change observed in C1 cells
(Figure 8b). Additionally, SMAD2 as well as its cofactor SMAD4 had increased transcript
levels solely in ΔCD cells (p<0.05) (Figure 8c).
To corroborate the observation of increased SMAD2 phosphorylation in ΔCD cells, the
expression of genes known to be regulated through canonical TGF-β signalling were
quantified. Solute carrier family 39 member 1 (SLC39A1) (Özdemir et al., 2014), cyclin
dependent kinase inhibitor 1A (CDKN1A) (Liu et al., 2010), ETS homologous factor
(EHF) (Yamazaki et al., 2015), bone marrow stromal cell antigen 2 (BST2) (Sayeed et al.,
2013), and tumour protein P53 inducible nuclear protein 1 (TP53INP1) (Liu et al., 2015)
are select genes known to be either upregulated or downregulated in response to TGF-β
treatment. Thus, corresponding changes in their RNA levels were used to confirm

47

Figure 7. Cells with MT1-MMP lacking its cytoplasmic domain have an altered
profile of TGF-β1 levels.
(a) qPCR analysis of parental MCF-7, C1, and ΔCD cell lines revealed similar
expression of genes associated with epithelial-mesenchymal transition. No statistically
significant changes were observed in SNAI1, CDC42, CDH1, ITGB1, or BSG levels.
However, ΔCD cells had a significant decrease in TGFB1 expression relative to parental
MCF-7 cells (p≤0.05). The results of four biological replicates are shown as log2
transformed mean fold-change ± SEM and were compared using one-way ANOVA and
Tukey’s post-hoc test; *, p ≤ 0.05. (b) Representative immunoblot image (left) of
intracellular TGF-β1 protein level in parental MCF-7, C1, and ΔCD cells. Western blot
analysis was used to determine if a reduction of TGFB1 expression as seen via qPCR
resulted in altered TGF-β1 protein levels. No change of intracellular TGF-β1 (44 kDa)
sequestered in its small latency complex (SLC) was observed between cell lines
following densitometry quantification (right). Band intensities were normalized to β-actin
before comparison to parental MCF-7 cells. Means from three biological replicates are
presented as mean arbitrary units (a.u.) ± SEM and were analyzed using one-way
ANOVA.
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Figure 8. Deletion of the cytoplasmic domain of MT1-MMP increased canonical
SMAD2-dependent TGF-β signalling.
(a) Expression of different TGF-β isoforms and receptors was assessed using qPCR
analysis. TGFB1 decreased in ΔCD, however, expression of TGFB2, TGFB3, and
TGFBR3 increased relative to parental MCF-7 cells (p ≤ 0.05). No change was observed
in C1 cells relative to parental MCF-7 cells. The results of three biological replicates are
shown as log2 transformed mean fold-change ± SEM and were compared using one-way
ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05. (b) Representative immunoblot image
(left) of phospho-SMAD2 (60 kDa) and total SMAD2 (58 kDa) protein levels in parental
MCF-7, C1, and ΔCD cells. An increase in the relative level of SMAD2 phosphorylation
was observed solely in ΔCD cells. Densitometry quantification (right) of three biological
replicates are shown, with phospho-SMAD2 normalized to total SMAD2 for each sample
before comparison to parental MCF-7. Means are presented as arbitrary units (a.u.) ±
SEM and were analyzed using one-way ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05.
(c) qPCR analysis of SMAD2 and SMAD4 in all cell lines. ΔCD cells have significantly
higher expression of SMAD2 and SMAD4 (p ≤ 0.05) relative to parental MCF-7 cells.
Log2 transformed mean fold-change ± SEM from three biological replicates were
compared using one-way ANOVA and Tukey’s post-hoc test; *, p ≤ 0.05; ***, p ≤ 0.001.
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downstream effects of the different TGF-β/SMAD2 levels observed between the cell
lines.
As ΔCD cells increased phospho-SMAD2 levels, genes that have been shown to be
upregulated through TGF-β signalling – SLC39A1, CDKN1A, and EHF – should have
elevated RNA levels in ΔCD cells. Indeed, SLC39A1 expression increased 1.5-fold
(p<0.01) in ΔCD cells, but not C1 (Figure 9). In contrast, EHF expression was 6.2-fold
higher (p<0.01) in C1 cells relative to parental MCF-7 cells. CDKN1A (aka P21) did not
change its expression levels in any cell line. Conversely, previous research has linked
TGF-β signalling with the downregulation of BST2 and TP53INP1. Accordingly, a
decrease in expression was expected in ΔCD cells. BST2 levels decreased 3.1-fold
(p<0.001) in C1 and 16.4-fold (p<0.0001) in ΔCD cells. No change in TP53INP1 RNA
level was observed in any cell line relative to parental MCF-7 cells.
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Figure 9. Observed increase of SMAD-dependent TGF-β signalling in ΔCD cells
resulted in increase of SLC39A1 and decrease of BST2 expression in ΔCD
cells.
Genes previously known to be up- or down-regulated by TGF-β signalling were analyzed
with qPCR. SLC39A1, CDKN1A, and EHF have been shown to be upregulated through
the canonical TGF-β/SMAD pathway. Increased expression of SLC39A1 (p<0.01) and
EHF (p<0.01) were observed in ΔCD and C1 cells, respectively. No change in CDKN1A
expression occurred in either cell line. Conversely, BST2 and TP53INP1 were previously
observed to be downregulated following TGF-β treatment. Expression of BST2
significantly decreased in C1 (p<0.001) and ΔCD (p<0.0001) cells, with no change
observed in TP53INP1 expression. Three biological replicates are shown as log2
transformed mean fold-change ± SEM and were compared using one-way ANOVA and
Tukey’s post-hoc test; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.
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4

DISCUSSION

The aim of this study was to generate a catalog of proteins that associate with MT1-MMP
to corroborate previous research of MT1-MMP-mediated proteolytic and cell signalling
functions. Using MCF-7 breast cancer cells, stable cell lines were previously created that
overexpress MT1-MMP (C1) or express MT1-MMP lacking its cytoplasmic domain
(ΔCD). I hypothesized that the diverse functions of MT1-MMP are dependent on
domain-specific binding partners that elucidate a cellular response. The first objective of
the study was to identify putative MT1-MMP binding partners, and 248 unique proteins
were isolated following MT1-MMP pulldown and identified with mass spectrometry.
Secondly, comparison of binding partners isolated from full-length and truncated
MT1-MMP expressing cells identified differences in KEGG pathway enrichment. In
particular, the cytoplasmic domain may be required for protein-protein interactions that
facilitate MT1-MMP localization. Finally, the cytoplasmic domain of MT1-MMP is
involved in cell signalling pathways as indicated by an increase in canonical TGF-β
signalling within ΔCD cells.
4.1

Identification of MT1-MMP binding partners and similarities to previous
MT1-MMP proteomic research

In this study, 248 proteins (Appendix B) were coimmunoprecipitated with MT1-MMP
and identified via mass spectrometry in parental MCF-7, C1, and ΔCD cells. Although
939 proteins were identified in MCF-7 cells, 919 in C1 cells, and 1051 in ΔCD, stringent
filtering criteria was used to eliminate non-specific proteins. Firstly, proteins needed to be
identified by at least 1 unique peptide and isolated in ³2 biological replicates. Second,
pulldown with a rabbit IgG antibody was used as a negative control to identify proteins
that may non-specifically associate with the MT1-MMP rabbit antibody or beads. Third,
ribosomes and proteins that were associate with the spliceosome pathway (Appendix A)
were removed due to their identification as common contaminants (Gingras et al., 2007).
Ribosomal and spliceosome-related proteins were also observed to be enriched in the
anti-rabbit IgG pulldown. Following removal of non-specific proteins, the final dataset
included ~15% of the total number of proteins that were originally isolated with
anti-MT1-MMP immunoprecipitation (Figure 5a). Since label-free
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coimmunoprecipitation relies on a single step affinity purification, it is estimated that true
interaction partners represent ~10% of originally identified proteins (Nesvizhskii, 2012).
The number of true interactions being 15% of the total number of proteins originally
isolated in this study is within this magnitude.
In the identification of false positives, many proteins are recognized as common
contaminants and subsequently excluded from analysis. Typically, these proteins are
highly abundant (e.g. tubulins and actins) or involved in disrupted protein folding (e.g.
heat shock proteins and chaperones) (Gingras et al., 2007; Nesvizhskii, 2012). Highly
abundant proteins, and those involved in disrupted protein folding, were isolated with
MT1-MMP. However, a limitation of affinity purification and mass spectrometry is its
inability to decipher a multiplicity of associations (Gingras et al., 2007). These proteins
can have dramatically different roles as determined by which distinct, yet biologically
relevant, complex they are associated with. For this reason, these proteins (e.g. tubulins,
actin, or HSPs) were not removed from the dataset even though they are commonly
identified as false positives.
Several studies have identified MT1-MMP binding partners using a bottom-up proteomic
approach. From this, approximately 400 unique proteins have been catalogued as
potential MT1-MMP binding partners (Butler et al., 2008; Hwang et al., 2004; Niiya et
al., 2009; Stegemann et al., 2013; Tam et al., 2004; Tomari et al., 2009). In agreement
with previous studies, 26 of the 248 proteins identified here have been reported as MT1MMP binding partners (Table 4). These proteins include extracellular matrix components
(laminin and vitronectin), receptors (transferrin receptor and receptor of activated protein
C kinase), and various signalling molecules (G proteins). The catalog of binding partners
identified in MT1-MMP proteomic studies contains approximately 400 proteins.
However, complete lists of binding partners were not provided in all studies which
indicates this catalog is much larger. For instance, Tam et al., (2004) provided only a
subset of 17 identified binding partners whereas their original dataset contained over 100
proteins. Similarly, Butler et al., (2008) only considered biochemically validated proteins.
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Table 4. Proteins identified in this study that have been previously identified in
other proteomic-based MT1-MMP studies.
UniProtKB
Accession
Number
Protein Name
O15230
O43291
O60884
O95816
P02765
P02786
P04004
P04843
P05023
P08107
P08195
P08754
P10909
P11021
P31689
P35221
P35222
P50402
P62873
P63244
P78371
Q01650
Q13162
Q13501
Q9BUF5
Q9UIQ6

Laminin subunit alpha-5
Kunitz-type protease inhibitor 2
DnaJ homolog subfamily A member 2
BAG family molecular chaperone regulator 2
Alpha-2-HS-glycoprotein
Transferrin receptor protein 1
Vitronectin
Dolichyl-diphosphooligosaccharide--protein
glycosyltransferase subunit 1
Sodium/potassium-transporting ATPase subunit alpha-1
Heat shock 70 kDa protein 1A/1B
4F2 cell-surface antigen heavy chain
Guanine nucleotide-binding protein G(k) subunit alpha
Clusterin
78 kDa glucose-regulated protein
DnaJ homolog subfamily A member 1
Catenin alpha-1
Catenin beta-1
Emerin
Guanine nucleotide-binding protein G(I)/G(S)/G(T)
subunit beta-1
Guanine nucleotide-binding protein subunit beta-2-like 1
(Receptor of activated protein C kinase 1)
T-complex protein 1 subunit beta
Large neutral amino acids transporter small subunit 1
Peroxiredoxin-4
Sequestosome-1
Tubulin beta-6 chain
Leucyl-cystinyl aminopeptidase

Reference(s)
1
2, 4
3
3
5
3, 4
5
3
3
4
3
4
5
3, 4
3, 4
3, 4
4
4
3
4
3
3
3
3, 4
3
3

1

Stegemann et al., 2013; 2 Butler et al., 2008; 3 Tomari et al., 2009; 4 Niiya et al., 2009;

5

Hwang et al., 2004

No accession numbers were provided in Niiya et al., 2009.
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Finally, Niiya et al., (2009) did not provide accession numbers of the proteins identified
in the study. Due to the historically unpredictable nature of protein naming, a proper
comparison could not be completed.
It is important to note that although only ~10% of proteins pulled down in this study have
been previously identified, the affinity purification methodology employed in this work
differed drastically. In previous studies, the use of tagged MT1-MMP (for easy isolation)
or catalytically inactive MT1-MMP (to prevent degradation of binding partners) could
alter MT1-MMP–protein complex formation, unlike native MT1-MMP used in this study.
4.2

Validation of select binding partners

As 248 proteins were identified by mass spectrometry as putative MT1-MMP binding
partners, I sought to validate the utility of the co-immunoprecipitation. Pulldown of
MT1-MMP followed by immunoblot analysis confirmed MT1-MMP interactions with
vitronectin, hyaluronan-mediated motility receptor, and fragile X mental retardation
protein 1 (Figure 6).
Vitronectin is a multifunctional extracellular glycoprotein commonly involved in
cell-ECM adhesion. MT1-MMP mediated degradation of vitronectin was previously
observed in human plasma incubated with a soluble MT1-MMP catalytic domain (Hwang
et al., 2004). While observed in parental cells, vitronectin was not identified following
MT1-MMP pulldown from ΔCD cells by mass spectrometry nor immunoblotting
(Appendix B, Figure 6). This is not due to an inability of MT1-MMP to digest vitronectin
as MT1-MMP lacking its transmembrane and cytoplasmic domain cleaved vitronectin
into two distinct fragments (Ohuchi et al., 1997). Rather, improper localization or
recycling of ΔCD MT1-MMP (section 4.4.3) could result in perpetual inhibition by
TIMP-2 or other endogenous inhibitors. Although identified by mass spectrometry
following MT1-MMP pulldown in C1 cells, no visible band corresponding to vitronectin
was observed in the validation assay (Figure 6). Due to increased MT1-MMP expression
in C1 cells, these cells have higher levels of ECM degradation. For this reason,
vitronectin bound to MT1-MMP may be rapidly degraded to a level undetectable by
immunoblot analysis.
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The hyaluronan-mediated motility receptor belongs to a family of hyaladherins that share
the ability to bind hyaluronic acid (HA), an important component of the ECM and tumour
microenvironment. Despite its putative extracellular role, there are reports that
intracellular HMMR is involved in mitotic spindle integrity and cell cycle progression
(Entwistle et al., 1996). In this study, HMMR was isolated in parental MCF-7, C1, and
ΔCD cell lines. This alludes that the interaction with MT1-MMP is most likely occurring
at the cell surface and supports an extracellular role (Figure 6, Appendix B). This study is
the first to report a direct interaction between HMMR and MT1-MMP. However, HMMR
forms a complex with CD44 and HA on the cell surface to activate intracellular signalling
pathways, in particular MAPK via ERK1/2 activation (Turley et al., 1993; Zhang et al.,
1998). The interaction between MT1-MMP and CD44 has been extensively reported,
with localization of MT1-MMP to invadopodia and associated increase in cell migration
attributed to this interaction (Mori et al., 2002; Ridley et al., 1992). Since MT1-MMP,
CD44, and now purportedly HMMR can be clustered to invadopodia, both MT1-MMP
hemopexin-mediated binding and proteolytic shedding of HMMR may contribute to the
previously observed increase in ERK activation within these cell lines (Cepeda et al.,
2016, 2017b).
MT1-MMP not only co-immunoprecipitated with FMR1, but also two homologs that
interact with it: fragile X-related protein (FXR) 1 and FXR2 (Zhang et al., 1995; Figure
6, Appendix B). To date, research of FMR1 focuses on its role as a translation regulator
of proteins involved in cellular migration, motility, as well as adhesion and EMT (Lucá et
al., 2013). In particular, FMR1 modulates the expression of MMP-8 as well as TIMP-2
(Zalfa et al., 2017). For this reason, it is unsurprising that FMR1 is overexpressed in
various cancer, correlating with aggressive breast cancer markers. Interaction of
MT1-MMP with FMR1 or its homologs have not been previously reported. However, just
as MT1-MMP is localized at the leading edge of migrating cells, FMR1 is also
asymmetrically distributed with a front-rear polarity in cell migration (Zalfa et al., 2017).
Validation of vitronectin, HMMR, and FMR1 co-immunoprecipitation with MT1-MMP
further supports that other proteins identified in this study are true interactions.
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4.3

Involvement of binding partners in different pathways highlights the
diverse function of MT1-MMP

KEGG analysis of MT1-MMP binding partners identified enrichment within various
pathways (Table 2). Many of these networks have not been previously shown to involve
MT1-MMP functions. Protein involved in endocrine and other factor-regulated calcium
reabsorption pathways, pathogenic Escherichia coli infection, and Huntington’s disease
pathways were enriched within the catalog of MT1-MMP pulldown proteins. Upon
further examination, many of these proteins are part of cellular processes within the
identified pathway. For example, adaptor proteins and clathrin are key proteins involved
in endocytosis that may be dysfunctional within Huntington’s disease. Since KEGG
pathway analysis treats each pathway as a separate entity, it ignores the effect of shared
proteins involved in various cascades. For this reason, pathogenic E. coli infection,
Huntington’s disease, and endocrine and other factor-regulated calcium reabsorption
pathways are not necessarily indicative of MT1-MMP’s function within MCF-7 cells.
Involvement of MT1-MMP in other pathways such as RNA transport, RNA degradation,
and mRNA surveillance has also not been reported. However, MT1-MMP pulldown
proteins enriched in these KEGG pathways relate to a role in mRNA degradation. Mostly
centred around the nucleus, MT1-MMP binding partners (e.g. pinin/PNN) further support
that MT1-MMP can be translocated to the nucleus. Although MT1-MMP has no clear
nuclear localization sequence (NLS), furin recognition motifs between the pro- and
catalytic domain represent a bipartite NLS (Strongin, 2006). MT1-MMP interaction with
importin α implies that this method of transport to the nucleus may be occurring.
However, it is unknown whether this mechanism would specify between the transport of
pro- or active MT1-MMP. Regardless, MT1-MMP colocalizes with MMP-2 in nuclei of
liver tumours, correlating with poor survival (Ip et al., 2007). Immunoblot analysis of
nuclear MT1-MMP identified the 63 kDa active form as well as the 43 kDa degraded
form generated by MMP-2 processing, verifying that MT1-MMP and MMP-2 are
catalytically active within the nucleus. Additionally, Ip et al., (2007) observed
MT1-MMP transport to the perinuclear region in a caveolin-dependent manner, similar to
the nuclear translocation of insulin-like growth factor binding protein-3. Although the
function of MT1-MMP within the nucleus isn’t fully characterized, isolation of binding
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partners involved in mRNA degradation suggest a new potential role of MT1-MMP
within the nucleus/perinuclear region.
4.4

The cytoplasmic domain of MT1-MMP is required for protein export,
processing in the endoplasmic reticulum, and endocytosis

To better elucidate the role of domain-specific interactions, prey proteins isolated from
full-length MT1-MMP expressing cells (MCF-7 and/or C1), but not ΔCD cells, were
analyzed. KEGG pathway analysis identified enrichment within the 177 proteins isolated
in MCF-7 and C1 cells that was not observed in the 71 proteins isolated in ΔCD cells
(Figure 5). Of particular interest, there was an enrichment of proteins involved in protein
export, protein processing in the endoplasmic reticulum, and endocytosis (Table 3).
4.4.1 Protein export
Approximately 30% of all translated proteins are delivered to the endoplasmic reticulum,
most commonly by the signal recognition particle (SRP). Comprised of 6 proteins and a
7S SRP RNA, the SRP can be divided into two distinct domains – Alu domain and S
domains. Two different SRP proteins immunoprecipitated with MT1-MMP in the
parental MCF-7 and C1 cell lines. Of particular interest, SRP14 is a subunit of the Alu
domain whereas SRP72 is a subunit of the S domain (Akopian et al., 2013). No previous
research has identified an interaction between MMPs and the SRP. In fact, there has been
no reported protease involvement with the SRP. Since pro-MT1-MMP is commonly
activated in the trans-Golgi network, this SRP interaction is likely not enzyme/substrate
oriented. The lack of SRP components pulled down in ΔCD cells suggests that translation
of the complete protein is required for this interaction to occur. As a type-1
transmembrane protein, the cytoplasmic domain is translated last, with the other domains
(pro, catalytic, and hemopexin) already present in the ER lumen. Translation of ΔCD
MT1-MMP may not be completed properly due to the lack of expected charged amino
acid residues that would be found in the cytoplasmic domain. The SRP may detect this
anomaly. As a result, while the full-length protein remains bound to the SRP for further
functions or processing, the truncated protein is not.

61

4.4.2 Protein processing within the ER
In comparison with ΔCD, full-length MT1-MMP expressing cells co-immunoprecipitated
various proteins associated with quality control in the endoplasmic reticulum (i.e.
TRAPα, ribophorin 1, and Sec13). Translocon-associated protein subunit alpha (TRAPα)
discriminately binds misfolded proteins for efficient degradation upon unfolded protein
response (UPR) stimulation. TRAPα was isolated solely in C1 cells with a ~2500-fold
increase in MT1-MMP expression. Proper folding of this abnormally high level of protein
may be rate-limiting, and thus initiate the UPR. Under homeostatic conditions, however,
the TRAP complex associates with the translocon to properly fold newly translated
polypeptides (Ménétret et al., 2005). Another commonly associated translocon protein is
dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (ribophorin 1)
that facilitates N-glycosylation of newly synthesized proteins (Wilson et al., 2005).
MT1-MMP has two potential N-glycosylation sites at Asn229 in the catalytic domain and
Asn311 within the linker region (Boon et al., 2016). Although putative sequences are
found, inhibition of N-glycosylation doesn’t affect the glycosylation status of MT1-MMP
nor its cell surface localization (Remacle et al., 2006). Instead, ribophorin 1 interaction
with MT1-MMP may be related to protein folding in the ER (Wilson et al., 2005).
During translocation through the ER, MT1-MMP matures before transport to the Golgi
for further processing. A common mechanism of ER-Golgi transport is via coat protein
complex II (COPII)-coated vesicles. Interaction of full-length MT1-MMP with Sec13
indicates that transport from the ER to Golgi occurs in this manner as Sec proteins are
constituents of the COPII coat. Membrane proteins transported to the Golgi typically
contain an ER-export motif, which is characterized for MT1-MMP (Nufer et al., 2002).
The terminal valine of the cytoplasmic domain and dileucine motif near the C-terminus
act as ER export signals (Nufer et al., 2002; Ureña et al., 1999). However, MT1-MMP
lacking its cytoplasmic domain may still transport to the Golgi for further processing
since Sec16, an early mediator of COPII vesicle formation, was pulled down with
MT1-MMP in all cell lines (Hughes et al., 2009).
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4.4.3 Endocytosis
Endocytosis can regulate MT1-MMP activity by controlling the level of active
MT1-MMP on the cell surface as well as by removing TIMP-bound or otherwise
inhibited MT1-MMP from the surface. The LLY573 motif within the cytoplasmic domain
interacts with AP-2 to mediate clathrin-driven endocytosis (Uekita et al., 2001). Previous
research of the ΔCD cell line observed that cytoplasmic deletion increased the migration
of the cells in multiple assays (Cepeda et al., 2017b). Since ΔCD MT1-MMP mutants are
unable to activate MMP-2 nor degrade gelatin (Cepeda et al., 2017b), the increase in cell
migration is likely due to non-proteolytic mechanisms. This reduction in catalytic activity
may be related to the absence of clathrin-related machinery pulled down in ΔCD cells.
Since the MT1-MMP catalytic domain is rapidly inactivated by binding of TIMP-2 and
other inhibitors, surface-localized proteolytic function of MT1-MMP relies on a constant
supply of active MT1-MMP (Remacle et al., 2006). This supply is not solely dependent
on the biosynthetic pathway. Instead, endocytosed MT1-MMP can be recycled back to
the membrane during which any bound inhibitors dissociate. It appears that since ΔCD
MT1-MMP cannot bind endocytic machinery, ΔCD MT1-MMP is not properly
endocytosed via clathrin-coated vesicles. This reduction of endocytosis corroborates
previous observations that ΔCD MT1-MMP has punctate localization at the cell surface,
yet is unable to activate MMP-2 or degrade gelatin.
Following endocytosis, recycling of MT1-MMP to invasive protrusions of the plasma
membrane involves Rab GTPases. Rab GTPases are a family of Ras-related GTPases that
determine the specificity of vesicle transport. Rab-4, 5A, 7, and 8 co-localize with
MT1-MMP-positive vesicles and have been identified as regulatory components of
MT1-MMP exocytosis from the late endosome to invadopodia (Castro-Castro et al.,
2016). There are no reports regarding Rab10 and MT1-MMP recycling, however, Rab10
is closely related to Rab8. Rab8 is known to regulate polarized membrane transport to
invasive structures in MDA-MB-231 cells (Bravo-Cordero et al., 2007). Intracellular
MT1-MMP is compartmentalized in Rab8-positive vesicles to control cell surface
activity, but mobilized to the surface when cells are actively degrading the ECM (BravoCordero et al., 2007). This trafficking would mimic other membrane proteins that are
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retained intracellularly, but redistributed via Rab10 to the plasma membrane upon
stimulation (Sano et al., 2007). Due to the similarity in structure and vesicle localization,
Rab8 and Rab10 may share similar roles in the recycling of MT1-MMP to the cell
surface, especially since they are upregulated in cancer cells (He et al., 2002; Ip et al.,
2007). The cytoplasmic domain is required for proper MT1-MMP endocytosis and
recycling through its interaction with AP-2, clathrin, and Rab GTPases.
The cytoplasmic domain has been previously identified as a requirement for proper MT1MMP endocytosis, this may be due to truncated MT1-MMP being unable to interact with
AP-2, clathrin, or Rab GTPases.
4.5

Limitations of affinity-purified mass spectrometry

Although many proteins discovered in this analysis have been previously reported to
immunoprecipitated with MT1-MMP, some, such as MMP-2 (Will et al., 1996), CD44
(Kajita et al., 2001), or TIMP-2 (Will et al., 1996), were not isolated here. Due to the
sensitivity of mass spectrometry, extensive purification measures are required to remove
impurities and reduce the number of false positives. This is done at risk of losing weak
interactions that are biologically relevant (Vermeulen et al., 2008). During the
mechanical and chemical stresses of co-immunoprecipitation, bait-prey interactions may
be lost if the interaction is low-affinity or transient (Gingras et al., 2007). The affinity and
strength of an interaction is dictated by the type of bonds that form. For MT1-MMP,
hydrogen bonds form between its catalytic domain and substrate whereas covalent or
noncovalent bonds can form at other MT1-MMP domains (Overall, 2001). Accordingly,
catalytic binding partners such as MMP-2 and TIMP-2 would be more difficult to capture
than proteins that bind other MT1-MMP domains.
In addition to loss of protein-protein interactions during purification procedures,
commonly identified binding partners may be absent in the final dataset due to cell-type
specificity. In previous MT1-MMP proteomic studies, 163 and 158 proteins were
coimmunoprecipitated from A431 carcinoma and A375 melanoma cells, respectively.
Experimental procedures were identical in these studies, but only 61 proteins were shared
between them (Niiya et al., 2009; Tomari et al., 2009). It appears that the sensitivity of
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mass spectrometry is affected by sample complexity, with highly abundant proteins being
favoured. Although less common than false positives, false negatives typically occur
because of this reason; since interactions with lowly abundant proteins can masked by
highly abundant protein. Due to low abundance of MMP-2 and TIMP-2 in MCF-7 cells
(Cepeda et al., 2017a), the likelihood of pulldown with MT1-MMP is reduced. Similarly,
because the mass spectrometer operated using a FT/IT/CID Top 10 data-dependent mode,
highly abundant proteins are more likely to be identified than lowly abundant proteins.
Cell-type specific expression may explain why commonly reported MT1-MMP binding
partners (e.g. MMP-2 and TIMP-2) were not identified in this study as well as previous
studies (Niiya et al., 2009; Tomari et al., 2009).
Samples submitted for mass spectrometry are complex and provide a snapshot of
MT1-MMP interactions at the time of protein isolation. If the MT1-MMP–protein
interaction is weak, it may be lost during affinity purification procedures. In contrast, if
the cell has low expression of a binding partner, the interaction may not be occurring at
the time of cell lysate collection or it may be masked by higher abundant proteins during
mass spectrometry analysis. These issues highlight a disadvantage of unlabelled affinity
purification and mass spectrometry analysis: reproducibility between individual sample
preparations. In a previous MT1-MMP proteomic analysis, Butler et al., (2008) identified
269 different proteins from 3 biological replicates. However, of those 269 proteins, 65%
were identified in only one biological replicate, 28% were identified in two, and 7% were
identified in all three. Indeed, even in this present study, known MT1-MMP binding
proteins were identified (i.e. collagen 1α and TIMP-3), but only isolated within one
biological replicate. Since the criteria of a true interaction required isolation from ³2
biological replicates, these proteins were subsequently removed.
4.6

The cytoplasmic domain of MT1-MMP attenuates TGF-β signalling in
MCF-7 cells

MT1-MMP lacking its cytoplasmic domain has reduced proteolytic activity, yet ΔCD
cells, but not C1, were more migratory than parental MCF-7 cells (Cepeda et al., 2016,
2017b). This indicates that MT1-MMP has a non-proteolytic role in cell migration.
Increased migration of ΔCD cells is not due to changes in gene expression commonly
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observed in epithelial-mesenchymal transition (Figure 7a). However, a decrease in
TGFB1 expression was observed in ΔCD cells. Therefore, an objective of the study was
to identify any potential roles of the MT1-MMP cytoplasmic domain regarding cell
signalling pathways, in particular TGF-β signalling.
Originally, no change in intracellular small latency complex-bound TGF-β1 protein level
was observed (Figure 7b). However, no suitable TGF-β1 antibody, of the three utilized,
specifically corresponded with TGF-β1 or its associated complexes. Furthermore,
TGF-β1 is a secreted cytokine that is released from inhibitory complexes in the ECM
before it can function as a ligand. Thus, whole cell lysate used for immunoblot analysis
would not be indicative of extracellular TGF-β1 protein level. For this reason,
quantifying the level of intracellular SLC-bound TGF-β1 protein is not representative of
TGF-β1 protein level. In an attempt to quantify extracellular TGF-β1 protein level, cell
media was protein precipitated and immunoblotted. However, this was not successful.
Thus, SMAD2 phosphorylation was used to better understand if a reduction of TGFB1
resulted in a decrease in canonical TGF-β signalling
Altered levels of TGF-β genes in ΔCD cells ultimately resulted in increased
SMAD-dependent TGF-β signalling (Figure 8). Previously observed genes regulated by
TGF-β signalling had variable expression in ΔCD cells (Figure 9). However, expected
changes in response to increased TGF-β signalling were observed in some genes (e.g.
SLC39A1 and BST2). Other genes examined that did not change solely due to increased
SMAD-dependent TGF-β signalling may be modulated by multiple signalling pathways.
Altered TGF-β signalling is likely to occur through MT1-MMP-mediated liberation of
extracellular TGF-β isoforms from their inhibitory complexes (Nguyen et al., 2016).
MT1-MMP can cleave latent TGF-β binding proteins directly, but also indirectly through
pro-MMP-2 and pro-MMP-9 activation (Yu and Stamenkovic, 2000). However, MCF-7
cells are naturally deficient in MMP-2 and MMP-9 expression. Additionally, MT1-MMP
proteolytic activity in ΔCD cells is ablated (Cepeda et al., 2017b). For these reasons,
increased SMAD2 phosphorylation is likely not a result of increased free TGF-β ligand
that can bind its receptors. Rather, reduced MT1-MMP proteolytic activity in ΔCD cells
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maintains TGF-β receptor 3 (TGFβR3, betaglycan) at the cell surface. In contrast,
MT1-MMP in parental MCF-7 and C1 cells may shed TGF-β receptors, such as
betaglycan, from the cell surface (Velasco-Loyden et al., 2004). When bound to the
plasma membrane, betaglycan functions as a coreceptor, enhancing TGFβ affinity with
TGFβR2 to facilitate downstream signalling. However, when shed from the membrane,
betaglycan has an inverse effect by inhibiting TGF-β availability, especially the TGF-β2
isoform (López-Casillas et al., 1994; Velasco-Loyden et al., 2004). Reduced ΜΤ1-ΜΜP
catalytic activity in ΔCD cells (Cepeda et al., 2017b) would prevent betaglycan shedding,
thus increasing TGF-β signalling relative to parental MCF-7 and C1 cells.
4.7

Future directions

The work presented is a strong foundation on which future data mining of MT1-MMP
interacting partners and networks can be accomplished. To begin, although proteins
pulled down with MT1-MMP indicate an association, the functional consequences of the
interaction are unknown. The comparison of proteins isolated from full-length expressing
MT1-MMP cells with proteins isolated in ΔCD cells can help elucidate, but not confirm,
the outcome of an interaction. To that end, characterization of domain-specific binding,
cellular localization, and the outcome of an interaction regarding cell signalling or
degradation by-products should be evaluated first. Future work should aim to better
understand the translation of an MT1-MMP–protein interaction to other in vitro and in
vivo approaches. The MCF-7 cell line used in this study has low endogenous expression
of MT1-MMP. As such, overexpression of MT1-MMP may result in nonphysiologically
relevant MT1-MMP–protein interactions. An interaction should be confirmed using
another cell type, such as MDA-MB 231 cells, that have higher endogenous MT1-MMP
expression than MCF-7 cells. Additionally, since MT1-MMP remodels the ECM, in vitro
conditions such as growth on a synthetic ECM may impact the location and outcome of
an interaction. Finally, a transition from in vitro to in vivo studies would provide a more
comprehensive understanding of MT1-MMP function as dictated by its interaction with
various binding partners.
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5

CONCLUSION

Membrane-type 1 matrix metalloproteinase is a multifunctional enzyme involved in a
variety of cellular processes. As previous studies have identified binding partners of
MT1-MMP that contribute to its diverse function, the aim of this study was to generate a
catalog of proteins that associate with MT1-MMP to corroborate previous research
regarding the role of MT1-MMP in cell migration, invasion, and survival. Here, 248
proteins were isolated with MT1-MMP in MCF-7 cells, 26 of which have been
previously reported as MT1-MMP binding partners. Binding partners identified within
this study imply new putative MT1-MMP functions, such as RNA turnover or transport. I
hypothesized that these binding partner interactions, and subsequent cellular responses,
are MT1-MMP domain-specific. In this study, binding partners isolated from full-length
expressing MT1-MMP cells were compared with those isolated from cells that express a
truncated form of MT1-MMP lacking its cytoplasmic domain. KEGG enrichment analysis
suggests the cytoplasmic domain may be required for protein-protein interactions that
facilitate MT1-MMP function, such as proper processing in the ER, protein export, and
endocytosis. However, ΔCD cells have increased SMAD2 phosphorylation, indicating
that the cytoplasmic domain of MT1-MMP may attenuate canonical transforming growth
factor beta (TGF-β) signalling through an unknown mechanism. By contributing to the
expanding catalog of MT1-MMP binding partners, this work suggests new MT1-MMP
functions within MCF-7 cells.
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Appendices

Appendix A. Top 10 most significantly enriched KEGG pathways represented by 266 proteins co-immunoprecipitated with
MT1-MMP in parental MCF-7, C1, and ΔCD.
ID: KEGG Pathway

Count

Size

Genes

hsa03040: Spliceosome

19

130

CDC5L
PCBP1
RBMXL1
SRSF10

DDX5
PLRG1
RP9
SRSF3

DHX15
PRPF19
SART1
SRSF9

EIF4A3
PRPF8
SF3B4
TRA2B

HSPA1A
RBMX
SNW1

2.53 x 10-11

hsa03013: RNA transport

19

159

CASC3
EIF3I
FXR1
PNN

EIF2S1
EIF4A1
FXR2
RAN

EIF2S3
EIF4A3
NUP210
SEC13

EIF3C
EIF4G1
PABPC1
UPF1

EIF3CL
FMR1
PABPC4

3.21 x 10-10

hsa03018: RNA
degradation

12

77

CNOT1
DHX36
PABPC4

CNOT2
EDC4
XRN2

CNOT3
HSPA9

CNOT7
HSPD1

DDX6
PABPC1

1.49 x 10-7

hsa03015: mRNA
surveillance pathway

12

89

CASC3
PABPC1
UPF1

CPSF1
PABPC4
WDR33

CPSF2
PNN

EIF4A3
PPP1CA

FIP1L1
PPP1CC

4.87 x 10-7

hsa04141: Protein
processing in the
endoplasmic reticulum

12

161

BAG2
HSP90AB
1
SEC13

DNAJA1
HSPA1A

DNAJA2
HSPA5

EIF2S1
RPN1

HSP90AA1 0.00014
RRBP1

CTNNB1
YWHAQ

NCL
YWHAZ

TUBB2A

TUBB2B

TUBB6

hsa05130: Pathogenic
Escherichia coli infection

7

53

FDR

SSR1
0.00045
85

(Appendix A continued)
Count

Size

Genes

hsa05016: Huntington’s
disease

10

193

AP2A1
ATP5C1

AP2B1
CLTC

AP2M1
DCTN1

ATP50
NDUFA4

ATP5A1
SLC25A5

0.011

hsa04961: Endocrine and
other factor-regulated
calcium reabsorption

5

47

AP2A1

AP2B1

AP2M1

ATP1A1

CLTC

0.0144

hsa04261: Adrenergic
signaling in cardiomyocytes

8

139

ATP1A1
PPP1CC

ATP2A2
TPM1

CALM1
TPM3

GNAI3

PPP1CA

0.0167

hsa03450: Non-homologous
end-joining

3

13

PRKDC

XRCC5

XRCC6

ID: KEGG Pathway

FDR

0.0209

Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, False Discovery Rate
Notes: Count: number of genes isolated within pathway; Size: total number of genes in pathway
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Appendix B. Final list of 248 MT1-MMP associating proteins identified by LC-MS/MS within MCF-7 cell lines.
UniProtKB
Symbol
EIFCL
AGRIN
NOP56
TRAD1
LAMA5
CASC3

O60264

SMCA5

O60884
O75534
O76094
O95047
O95782
O95816
O96019
P05198
P07900
P07951
P08754
P09493
P10809
P19338

DNJA2
CSDE1
SRP72
OR2A4
AP2A1
BAG2
ACL6A
IF2A
HS90A
TPM2
GNAI3
TPM1
CH60
NUCL

Protein Name
Eukaryotic translation initiation factor 3 subunit C-like protein
Agrin
Nucleolar protein 56
TRAF-type zinc finger domain-containing protein 1
Laminin subunit alpha-5
Protein CASC3
SWI/SNF-related matrix-associated actin-dependent regulator of
chromatin subfamily A member 5
DnaJ homolog subfamily A member 2
Cold shock domain-containing protein E1
Signal recognition particle subunit SRP72
Olfactory receptor 2A4
AP-2 complex subunit alpha-1
BAG family molecular chaperone regulator 2
Actin-like protein 6A
Eukaryotic translation initiation factor 2 subunit 1
Heat shock protein HSP 90-alpha
Tropomyosin beta chain
Guanine nucleotide-binding protein G(k) subunit alpha
Tropomyosin alpha-1 chain
60 kDa heat shock protein mitochondrial
Nucleolin

MCF-7
+
+
+
+
+
+

C1
–
–
–
–
–
–

ΔCD
–
–
–
–
–
–

+

–

–

+
+
+
+
+
+
+
+
+
+
+
+
+
+

–
–
–
–
–
–
–
–
–
–
–
–
–
–

–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
B5ME19
O00468
O00567
O14545
O15230
O15234

UniProtKB
Symbol
DNJA1
PP1G
IF2G
LAP2A
EFTU
EMD
DSRAD
IF4A1
ARP3
PP1A
GBB1
GBB2
1433Z
TCPB
PRKDC
KIF23
KRR1
RBM39
UBP10
PLEC
SF01
PRC2B
ZC3HD
MBNL2

Protein Name
DnaJ homolog subfamily A member 1
Serine/threonine-protein phosphatase PP1-gamma catalytic subunit
Eukaryotic translation initiation factor 2 subunit 3
Lamina-associated polypeptide 2 isoform alpha
Elongation factor Tu mitochondrial
Emerin
Double-stranded RNA-specific adenosine deaminase
Eukaryotic initiation factor 4A-I
Actin-related protein 3
Serine/threonine-protein phosphatase PP1-alpha catalytic subunit
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2
14-3-3 protein zeta/delta
T-complex protein 1 subunit beta
DNA-dependent protein kinase catalytic subunit
Kinesin-like protein KIF23
KRR1 small subunit processome component homolog
RNA-binding protein 39
Ubiquitin carboxyl-terminal hydrolase 10
Plectin
Splicing factor 1
Protein PRRC2B
Zinc finger CCCH domain-containing protein 13
Muscleblind-like protein 2

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
P31689
P36873
P41091
P42166
P49411
P50402
P55265
P60842
P61158
P62136
P62873
P62879
P63104
P78371
P78527
Q02241
Q13601
Q14498
Q14694
Q15149
Q15637
Q5JSZ5
Q5T200
Q5VZF2

UniProtKB
Symbol
DHX57
EDC4
CNST
ANKH1
PLPL6
ABCF1
DDX54
LAR4B
RAB1C
LRC59
PCD16
RBM14
EIF3C
MMTA2
TBB6
REPI1
RBM4
YTHD1
BTBD1
XRN2
RAB1B
PININ
MBNL1
ARP3B

Protein Name
Putative ATP-dependent RNA helicase DHX57
Enhancer of mRNA-decapping protein 4
Consortin
Ankyrin repeat and KH domain-containing protein 1
Neuropathy target esterase
ATP-binding cassette sub-family F member 1
ATP-dependent RNA helicase DDX54
La-related protein 4B
Putative Ras-related protein Rab-1C
Leucine-rich repeat-containing protein 59
Protocadherin-16
RNA-binding protein 14
Eukaryotic translation initiation factor 3 subunit C
Multiple myeloma tumor-associated protein 2
Tubulin beta-6 chain
Replication initiator 1
RNA-binding protein 4
YTH domain family protein 1
BTB/POZ domain-containing protein 1
5'-3' exoribonuclease 2
Ras-related protein Rab-1B
Pinin
Muscleblind-like protein 1
Actin-related protein 3B

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

89

UniProtKB
Accession
Number
Q6P158
Q6P2E9
Q6PJW8
Q8IWZ3
Q8IY17
Q8NE71
Q8TDD1
Q92615
Q92928
Q96AG4
Q96JQ0
Q96PK6
Q99613
Q9BU76
Q9BUF5
Q9BWE0
Q9BWF3
Q9BYJ9
Q9H0C5
Q9H0D6
Q9H0U4
Q9H307
Q9NR56
Q9P1U1

UniProtKB
Symbol
LCAP
CNOT7
AGO2
ZC3H4
PKP3
NDUA4
SPIT2
CALU
CCNK
TRI37
FETUA
TFR1
AT1A1
SYEP
CLUS
AT2A2
CTNA1
RFC3
ECHA
SSRA
ATPO
TXTP
P5CS
ECHB

Protein Name
Leucyl-cystinyl aminopeptidase
CCR4-NOT transcription complex subunit 7
Protein argonaute-2
Zinc finger CCCH domain-containing protein 4
Plakophilin-3
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4
Kunitz-type protease inhibitor 2
Calumenin
Cyclin-K
E3 ubiquitin-protein ligase TRIM37
Alpha-2-HS-glycoprotein
Transferrin receptor protein 1
Sodium/potassium-transporting ATPase subunit alpha-1
Bifunctional glutamate/proline--tRNA ligase
Clusterin
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Catenin alpha-1
Replication factor C subunit 3
Trifunctional enzyme subunit alpha mitochondrial
Translocon-associated protein subunit alpha
ATP synthase subunit O mitochondrial
Tricarboxylate transport protein mitochondrial
Delta-1-pyrroline-5-carboxylate synthase
Trifunctional enzyme subunit beta mitochondrial

MCF-7
+
+
+
+
+
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

C1
–
–
–
–
–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
Q9UIQ6
Q9UIV1
Q9UKV8
Q9UPT8
Q9Y446
O00483
O43291
O43852
O75909
O94972
P02765
P02786
P05023
P07814
P10909
P16615
P35221
P40938
P40939
P43307
P48047
P53007
P54886
P55084

UniProtKB
Symbol
RAB1A
RAN
CLH1
LAT1
NSUN2
CPSF1
TBB2A
MAP7
MCM6
GAPD1
MLF2
IMMT
RBBP6
LSR
PCAT1
S35B2
STON2
DYL2
TBB2B
WDR33
RRBP1
CPSF2
DHCR7
UBP16

Protein Name
Ras-related protein Rab-1A
GTP-binding nuclear protein Ran
Clathrin heavy chain 1
Large neutral amino acids transporter small subunit 1
tRNA (cytosine(34)-C(5))-methyltransferase
Cleavage and polyadenylation specificity factor subunit 1
Tubulin beta-2A chain
Ensconsin
DNA replication licensing factor MCM6
GTPase-activating protein and VPS9 domain-containing protein 1
Myeloid leukemia factor 2
Mitochondrial inner membrane protein
E3 ubiquitin-protein ligase RBBP6
Lipolysis-stimulated lipoprotein receptor
Lysophosphatidylcholine acyltransferase 1
Adenosine 3'-phospho 5'-phosphosulfate transporter 1
Stonin-2
Dynein light chain 2 cytoplasmic
Tubulin beta-2B chain
pre-mRNA 3' end processing protein WDR33
Ribosome-binding protein 1
Cleavage and polyadenylation specificity factor subunit 2
7-dehydrocholesterol reductase
Ubiquitin carboxyl-terminal hydrolase 16

MCF-7
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–

C1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
P62820
P62826
Q00610
Q01650
Q08J23
Q10570
Q13885
Q14244
Q14566
Q14C86
Q15773
Q16891
Q7Z6E9
Q86X29
Q8NF37
Q8TB61
Q8WXE9
Q96FJ2
Q9BVA1
Q9C0J8
Q9P2E9
Q9P2I0
Q9UBM7
Q9Y5T5

UniProtKB
Symbol
CCAR2
DDX21
CNOT1
CNOT3
STAU1
VTNC
RPN1
4F2
HS90B
GRP78
C1TC
XRCC6
XRCC5
CTNB1
SRP14
GRP75
LAP2B
CAPZB
PRC2A
SMCA4
IMA1
SEC13
RAB10
CALM

Protein Name
Cell cycle and apoptosis regulator protein 2
Nucleolar RNA helicase 2
CCR4-NOT transcription complex subunit 1
CCR4-NOT transcription complex subunit 3
Double-stranded RNA-binding protein Staufen homolog 1
Vitronectin
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1
4F2 cell-surface antigen heavy chain
Heat shock protein HSP 90-beta
78 kDa glucose-regulated protein
C-1-tetrahydrofolate synthase cytoplasmic
X-ray repair cross-complementing protein 6
X-ray repair cross-complementing protein 5
Catenin beta-1
Signal recognition particle 14 kDa protein
Stress-70 protein mitochondrial
Lamina-associated polypeptide 2 isoforms beta/gamma
F-actin-capping protein subunit beta
Protein PRRC2A
Transcription activator BRG1
Importin subunit alpha-1
Protein SEC13 homolog
Ras-related protein Rab-10
Calmodulin

MCF-7
–
–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
–
–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
+
+
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
Q8N163
Q9NR30
A5YKK6
O75175
O95793
P04004
P04843
P08195
P08238
P11021
P11586
P12956
P13010
P35222
P37108
P38646
P42167
P47756
P48634
P51532
P52292
P55735
P61026
P62158

UniProtKB
Symbol
AP2B1
HBA
ARF5
PURA
AHNK
TADBP
PRDX4
KEAP1
UBP2L
DCTN1
SRC8
NBR1
DECR
ACTBL
ARID2
ESRP1
ZC3HE
FIP1
LARP4
DHX30
ZCCHV
FA98A
PO210
RENT1

Protein Name
AP-2 complex subunit beta
Hemoglobin subunit alpha
ADP-ribosylation factor 5
Transcriptional activator protein Pur-alpha
Neuroblast differentiation-associated protein AHNAK
TAR DNA-binding protein 43
Peroxiredoxin-4
Kelch-like ECH-associated protein 1
Ubiquitin-associated protein 2-like
Dynactin subunit 1
Src substrate cortactin
Next to BRCA1 gene 1 protein
2 4-dienoyl-CoA reductase mitochondrial
Beta-actin-like protein 2
AT-rich interactive domain-containing protein 2
Epithelial splicing regulatory protein 1
Zinc finger CCCH domain-containing protein 14
Pre-mRNA 3'-end-processing factor FIP1
La-related protein 4
Putative ATP-dependent RNA helicase DHX30
Zinc finger CCCH-type antiviral protein 1
Protein FAM98A
Nuclear pore membrane glycoprotein 210
Regulator of nonsense transcripts 1

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
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UniProtKB
Accession
Number
P63010
P69905
P84085
Q00577
Q09666
Q13148
Q13162
Q14145
Q14157
Q14203
Q14247
Q14596
Q16698
Q562R1
Q68CP9
Q6NXG1
Q6PJT7
Q6UN15
Q71RC2
Q7L2E3
Q7Z2W4
Q8NCA5
Q8TEM1
Q92900

UniProtKB
Symbol
TM159
AP2M1
PURB
RBM15
MOV10
E41L5
ARGL1
LYAR
CNOT2
ABCF2
CNO11
SRRM2
SYFA
YTHD2
TCPA
ERH
MPCP
PCBP2

Q969G3

SMCE1

P22087
P61962
Q13347
Q9BUT9

FBRL
DCAF7
EIF3I
F195A

Protein Name
Promethin
AP-2 complex subunit mu
Transcriptional activator protein Pur-beta
Putative RNA-binding protein 15
Putative helicase MOV-10
Band 4.1-like protein 5
Arginine and glutamate-rich protein 1
Cell growth-regulating nucleolar protein
CCR4-NOT transcription complex subunit 2
ATP-binding cassette sub-family F member 2
CCR4-NOT transcription complex subunit 11
Serine/arginine repetitive matrix protein 2
Phenylalanine--tRNA ligase alpha subunit
YTH domain family protein 2
T-complex protein 1 subunit alpha
Enhancer of rudimentary homolog
Phosphate carrier protein mitochondrial
Poly(rC)-binding protein 2
SWI/SNF-related matrix-associated actin-dependent regulator of
chromatin subfamily E member 1
rRNA 2'-O-methyltransferase fibrillarin
DDB1- and CUL4-associated factor 7
Eukaryotic translation initiation factor 3 subunit I
Protein FAM195A

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
–
–
–
–

C1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
–
–
–
–
–
–
–
–
–
–
–
–
–
–
+
+
+
+

–

+

+

+
+
+
+

–
–
–
–

+
+
+
+
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UniProtKB
Accession
Number
Q96B96
Q96CW1
Q96QR8
Q96T37
Q9HCE1
Q9HCM4
Q9NWB6
Q9NX58
Q9NZN8
Q9UG63
Q9UKZ1
Q9UQ35
Q9Y285
Q9Y5A9
P17987
P84090
Q00325
Q15366

UniProtKB
Symbol
NAT10
DDX3X
SC16A
HMMR
ADT2
IF4E
TPM3
HSP71
PABP1
YBOX3
SFPQ
ATPA
DDX6
PTBP1
1433T
RFC1
ATPG
MATR3
FXR1
FXR2
CAZA1
DYL1
GBLP
YBOX1

Protein Name
N-acetyltransferase 10
ATP-dependent RNA helicase DDX3X
Protein transport protein Sec16A
Hyaluronan mediated motility receptor
ADP/ATP translocase 2
Eukaryotic translation initiation factor 4E
Tropomyosin alpha-3 chain
Heat shock 70 kDa protein 1A/1B
Polyadenylate-binding protein 1
Y-box-binding protein 3
Splicing factor proline- and glutamine-rich
ATP synthase subunit alpha mitochondrial
Probable ATP-dependent RNA helicase DDX6
Polypyrimidine tract-binding protein 1
14-3-3 protein theta
Replication factor C subunit 1
ATP synthase subunit gamma mitochondrial
Matrin-3
Fragile X mental retardation syndrome-related protein 1
Fragile X mental retardation syndrome-related protein 2
F-actin-capping protein subunit alpha-1
Dynein light chain 1 cytoplasmic
Guanine nucleotide-binding protein subunit beta-2-like 1
Nuclease-sensitive element-binding protein 1

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
–
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
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UniProtKB
Accession
Number
Q9H0A0
O00571
O15027
O75330
P05141
P06730
P06753
P08107
P11940
P16989
P23246
P25705
P26196
P26599
P27348
P35251
P36542
P43243
P51114
P51116
P52907
P63167
P63244
P67809

UniProtKB
Symbol
TPM4
EWS
IF4G1
FMR1

Q07666

KHDR1

Q08211
Q12905
Q12906
Q13283
Q13310
Q13501
Q14004
Q14444
Q15007
Q15717
Q3MHD2
Q6PKG0
Q7Z417
Q86U86
Q8NC51
Q8TAQ2
Q8WWM7
Q92499

DHX9
ILF2
ILF3
G3BP1
PABP4
SQSTM
CDK13
CAPR1
FL2D
ELAV1
LSM12
LARP1
NUFP2
PB1
PAIRB
SMRC2
ATX2L
DDX1

Protein Name
Tropomyosin alpha-4 chain
RNA-binding protein EWS
Eukaryotic translation initiation factor 4 gamma 1
Fragile X mental retardation protein 1
KH domain-containing RNA-binding signal transduction-associated
protein 1
ATP-dependent RNA helicase A
Interleukin enhancer-binding factor 2
Interleukin enhancer-binding factor 3
Ras GTPase-activating protein-binding protein 1
Polyadenylate-binding protein 4
Sequestosome-1
Cyclin-dependent kinase 13
Caprin-1
Pre-mRNA-splicing regulator WTAP
ELAV-like protein 1
Protein LSM12 homolog
La-related protein 1
Nuclear fragile X mental retardation-interacting protein 2
Protein polybromo-1
Plasminogen activator inhibitor 1 RNA-binding protein
SWI/SNF complex subunit SMARCC2
Ataxin-2-like protein
ATP-dependent RNA helicase DDX1

MCF-7
+
+
+
+

C1
+
+
+
+

ΔCD
+
+
+
+

+

+

+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
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UniProtKB
Accession
Number
P67936
Q01844
Q04637
Q06787

UniProtKB
Accession
Number
Q92804
Q92841
Q99700
Q9BX70
Q9C0C2
Q9H4H8
Q9NYF8
Q9NZB2
Q9UN86
Q9Y224
Q9Y2W1
Q9Y3I0
Q9Y520

UniProtKB
Symbol
RBP56
DDX17
ATX2
BTBD2
TB182
FA83D
BCLF1
F120A
G3BP2
CN166
TR150
RTCB
PRC2C

Protein Name
TATA-binding protein-associated factor 2N
Probable ATP-dependent RNA helicase DDX17
Ataxin-2
BTB/POZ domain-containing protein 2
182 kDa tankyrase-1-binding protein
Protein FAM83D
Bcl-2-associated transcription factor 1
Constitutive coactivator of PPAR-gamma-like protein 1
Ras GTPase-activating protein-binding protein 2
UPF0568 protein C14orf166
Thyroid hormone receptor-associated protein 3
tRNA-splicing ligase RtcB homolog
Protein PRRC2C

MCF-7
+
+
+
+
+
+
+
+
+
+
+
+
+

C1
+
+
+
+
+
+
+
+
+
+
+
+
+

ΔCD
+
+
+
+
+
+
+
+
+
+
+
+
+
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